Patent Application
20240415904
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 11, 2022, is named 136923_00220_Sequence_listing.txt and is 791,898 bytes in size.
The present invention, in some embodiments thereof, relates to bacteriophage strains capable of infecting bacteria of the genus Staphylococcus, and more particularly bacteria of the species Staphylococcus aureus (SA) and Staphylococcus epidermis (SE) that are associated with skin disorders and disease, such as atopic dermatitis (AD) that was shown to be associated with increased skin colonization by Staphylococcus aureus. S. aureus contributes to AD pathogenesis through the release of virulence factors that affect the keratinocytes and immune cells. The relationship between AD and skin bacteria has led to different anti-microbial treatment approaches, including the use of bleach baths. Presently the use of bleach baths as an antibacterial therapy has shown mixed results, possibly due to varying concentrations of bleach used in different studies. Robust targeted and safe modulation of the microbiome may be more beneficial.
Phages are naturally occurring viruses that kill specific bacteria. Unlike antibiotics, phages are specific to the strain level and therefore, have unique advantages in terms of minimizing perturbation of the microbiome. They have no capability to infect mammalian cells and therefore, are considered safe.
Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
According to an aspect of the present invention there is provided a composition comprising at least two different strains of isolated bacteriophages, each capable of infecting a bacteria of the species Staphylococcus aureus, wherein at least one of the at least two different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to one of the nucleic acid sequence as set forth in SEQ ID NOs: 1-7.
According to an aspect of the present invention there is provided a composition comprising at least two different strains of isolated bacteriophages, each capable of infecting a bacteria of the species Staphylococcus aureus, wherein at least one of the at least two different strains of isolated bacteriophages has a genomic nucleic acid sequence comprising a combined region of homolog essential genes, at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to the combined coding region of the essential genes of a bacteriophage selected from the bacteriophages listed in Table 2, as set forth in Example 7.
According to an aspect of the present invention there is provided an isolated bacteriophage capable of infecting bacteria of the species Staphylococcus aureus, wherein the bacteriophage has a genomic nucleic acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to one of the nucleic acid sequences as set forth in SEQ ID NOs: 1-7.
According to an aspect of the present invention there is provided an isolated bacteriophage comprising at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical genes (e.g., in the combined region) to the essential genes of a bacteriophage selected from the phages listed in Table 2, wherein the essential genes for the selected bacteriophage are as set forth in Example 7.
According to an aspect of the present invention, the non-essential genomic region of the selected phage comprises all regions that are not listed as essential genes for the selected bacteriophage as set forth in Example 7.
According to an aspect of the present invention there is provided a recombinant (non-wild-type) bacteriophage capable of (lytically) infecting a bacteria of the species Staphylococcus aureus (e.g., Staphylococcus aureus present in a Atopic dermatitis patient), said recombinant bacteriophage has: (i) a genomic nucleic acid sequence comprising at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9%, or 100%) identical (e.g., in the combined coding region) to the essential genes of a bacteriophage selected from the bacteriophages listed in Table 2, as set forth in Example 7, and/or (ii) at least 200 bp of said recombinant bacteriophage non-essential genomic region deleted or otherwise mutated (e.g., for inactivating transposable elements).
According to an aspect of the present invention there is provided a recombinant (non-wild-type) bacteriophage capable of (lytically) infecting a bacteria of the species Staphylococcus aureus (e.g., Staphylococcus aureus present in a Atopic dermatitis patient), said recombinant bacteriophage has: (i) a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, or 99.9%) identical (e.g., in the combined coding region) to one of the nucleic acid sequence as set forth in SEQ ID NOs: 1-7, (ii) at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical genes (e.g. in the combined region) to the essential genes of a bacteriophage selected from the bacteriophages listed in Table 2, as set forth in Example 7, and/or (iii) at least 200 bp of said recombinant bacteriophage non-essential genomic region deleted or otherwise mutated (e.g., for inactivating transposable elements).
According to an aspect of the present invention there is provided a recombinant (non-wild-type) bacteriophage capable of (lytically) infecting a bacteria of the species Staphylococcus aureus (e.g., Staphylococcus aureus present in a Atopic dermatitis patient), said recombinant bacteriophage has: (i) a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9%, or 100%) identical in the combined coding region to one of the nucleic acid sequence as set forth in SEQ ID NOs: 1-7, (ii) at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical genes (e.g., in the combined region) to the essential genes of a bacteriophage selected from the bacteriophages listed in Table 2, as set forth in Example 7, and/or (iii) at least 200 bp of said recombinant bacteriophage non-essential genomic region deleted or otherwise mutated (e.g., for inactivating transposable elements).
According to an aspect of the present invention there is provided a method of treating a disease associated with a Staphylococcus aureus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising at least one isolated bacteriophage strain capable of infecting bacteria of the species Staphylococcus aureus, wherein the at least one bacteriophage strain has (i) a genomic nucleic acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to one of the nucleic acid sequences set forth in SEQ ID NOs: 1-7, and/or (ii) at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical genes (e.g., in the combined region) to the essential genes of a bacteriophage selected from the bacteriophages listed in Table 2, as set forth in Example 7; thereby treating the disease associated with a Staphylococcus aureus infection.
According to an aspect of the present invention there is provided a method of treating a disease associated with a Staphylococcus aureus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the composition described herein, thereby treating the disease associated with a Staphylococcus aureus infection.
According to an aspect of the present invention there is provided a recombinant bacteriophage capable of infecting bacteria of the species Staphylococcus aureus, wherein the bacteriophage has (i) a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to one of the nucleic acid sequences as set forth in SEQ ID NOs: 1-7, and/or (ii) at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical genes (e.g., in the combined region) to the essential genes of a bacteriophage selected from the bacteriophages listed in Table 2, as set forth in Example 7; and wherein the bacteriophage is genetically modified such that the genome thereof comprises a heterologous sequence.
According to an aspect of the present invention there is provided a pharmaceutical composition comprising the recombinant bacteriophage described herein as the active agent, and a pharmaceutical carrier.
According to an embodiment of the invention, a first of the at least two different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to the nucleic acid sequence as set forth in SEQ ID NO: 1 (and/or comprises the essential genes of phage STA48-1 as set forth in Example 7) and a second of the at least two different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to the nucleic acid sequence as set forth in SEQ ID NO: 7 (and/or comprises the essential genes of phage STA48-7 as set forth in Example 7).
According to an embodiment of the invention, the composition comprises at least three different strains of isolated bacteriophages, wherein a third of the at least three different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to the nucleic acid sequence as set forth in SEQ ID NO: 5 (and/or comprises the essential genes of phage STA48-5 as set forth in Example 7).
According to an embodiment of the invention, the composition comprises a bacteriophage or a combination of bacteriophages (e.g., a combination of 2, 3, or 4 bacteriophages), selected from:
In certain embodiments, the composition comprises a combination of 3 bacteriophages of (i)-(iii), such as a combination of 3 bacteriophages of (i) a bacteriophage having a genomic nucleic acid sequence of SEQ ID NO: 1 or the essential genes of phage STA48-1 as set forth in Example 7; (ii) a bacteriophage having a genomic nucleic acid sequence of SEQ ID NO: 7 or the essential genes of phage STA48-7 as set forth in Example 7; and (iii) a bacteriophage having a genomic nucleic acid sequence of SEQ ID NO: 5 or the essential genes of phage STA48-5 as set forth in Example 7.
In certain embodiments, the composition comprises a combination of 4 bacteriophages of (i)-(iv), such as a combination of 4 bacteriophages of (i) a bacteriophage having a genomic nucleic acid sequence of SEQ ID NO: 1 or the essential genes of phage STA48-1 as set forth in Example 7; (ii) a bacteriophage having a genomic nucleic acid sequence of SEQ ID NO: 7 or the essential genes of phage STA48-7 as set forth in Example 7; (iii) a bacteriophage having a genomic nucleic acid sequence of SEQ ID NO: 5 or the essential genes of phage STA48-5 as set forth in Example 7; and (iv) a bacteriophage having a genomic nucleic acid sequence of SEQ ID NO: 4 or the essential genes of phage STA48-4 as set forth in Example 7.
According to an embodiment of the invention, the at least two different strains of isolated bacteriophages in combination target at least 60, 72, 84, 96 or 108 different strains of Staphylococcus aureus from the list in Example 1.
According to an embodiment of the invention, the at least two different strains of isolated bacteriophages in combination target at least 5, 6 or 7 different clonal complexes of Staphylococcus aureus from the list in
According to an embodiment of the invention, the at least two different strains of isolated bacteriophages in combination target at least 14, 17, 20, 23, 26 or 29 different MLSTs of Staphylococcus aureus from the list in
According to an embodiment of the invention, at least 98, 72, 76, 80, 84 or 88 different strains of Staphylococcus aureus from the list in Example 1 are targeted by each of the at least two different strains.
According to an embodiment of the invention, at least 5, 6 or 7 different clonal complexes of Staphylococcus aureus from the list in
According to an embodiment of the invention, at least 10, 12, 14, 17, 20 or 23 different MLSTs of Staphylococcus aureus from the list in
According to an embodiment of the invention, the composition comprises at least three different strains of isolated bacteriophages, each capable of infecting a bacteria of the species Staphylococcus aureus, wherein each of the at least three (different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to one of the nucleic acid sequence as set forth in SEQ ID NOs: 1-7, and/or comprises the essential genes for a bacteriophage as specified in Example 7, wherein the at least three different strains of isolated bacteriophages in combination target (i) at least 80, 85, 90, 95, 100, 105 or 110 different strains of Staphylococcus aureus from the list in Example 1; and/or (ii) at least 14, 17, 20, 23, 26 or 29 different MLSTs of Staphylococcus aureus from the list in
According to an embodiment of the invention, the composition comprises at least three different strains of isolated bacteriophages, each capable of infecting a bacteria of the species Staphylococcus aureus, wherein each of the at least three different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to one of the nucleic acid sequence as set forth in SEQ ID Nos: 1-7, and/or comprises the essential genes for a bacteriophage as specified in Example 7, wherein (i) at least 65, 70, 75 or 80 different strains of Staphylococcus aureus from the list in Example 1; and/or (ii) at least 10, 12, 14, 17, 20 or 23 different MLSTs of Staphylococcus aureus from the list in
According to an embodiment of the invention, the at least one bacteriophage is genetically modified such that the genome thereof comprises a heterologous sequence.
According to an embodiment of the invention, the heterologous sequence encodes a therapeutic agent or a diagnostic agent.
According to an embodiment of the invention, the composition comprises no more than 7 different bacteriophage strains.
According to an embodiment of the invention, the heterologous sequence encodes a therapeutic agent or a diagnostic agent.
According to an embodiment of the invention, the therapeutic agent comprises an immune modulating agent.
According to an embodiment of the invention, the pharmaceutical composition is formulated for topical delivery, oral delivery or rectal delivery.
According to an embodiment of the invention, the disease is a Atopic dermatitis (AD).
According to an embodiment of the invention, the administering comprises topically administering or orally administering or rectally administering.
According to an embodiment of the invention, the method further comprises determining the strain of Staphylococcus aureus colonizing the subject prior to the administering.
According to an embodiment of the invention, the at least one bacteriophage strain is genetically modified such that the genome thereof comprises a heterologous sequence.
According to an embodiment of the invention, the heterologous sequence encodes a therapeutic agent or a diagnostic agent.
According to an embodiment of the invention, the therapeutic agent comprises an immune modulating agent.
Additional aspects and embodiments of the invention described here are provided below in the numbered paragraphs.
1. A composition comprising at least two different strains of isolated bacteriophages, each capable of (lytically) infecting a bacteria of the species Staphylococcus aureus (e.g., Staphylococcus aureus present in an Atopic Dermatitis patient), wherein at least one of said at least two different strains of isolated bacteriophages has (i) a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical (e.g., in the combined coding region) to one of the nucleic acid sequence as set forth in SEQ ID NOs: 1-7, and/or (ii) at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical genes (e.g., in the combined region) to the essential genes of a bacteriophage selected from the bacteriophages listed in Table 2, as set forth in Example 7; and
2. The composition of paragraph 1, wherein a first of said at least two different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical (e.g., in the combined coding region) to the nucleic acid sequence as set forth in SEQ ID NO: 1 and a second of said at least two different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical (e.g., in the combined coding region) to the nucleic acid sequence as set forth in SEQ ID NO: 7.
3. The composition of paragraph 2, comprising at least three different strains of isolated bacteriophages, wherein a third of said at least three different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical (e.g., in the combined coding region) to the nucleic acid sequence as set forth in SEQ ID NO: 5.
4. The composition of any one of paragraph 1-3, comprising:
5. The composition of any one of paragraphs 1-4, wherein said at least two different strains of isolated bacteriophages in combination target (a) at least 60, 72, 84, 96 or 108 different strains of Staphylococcus aureus from the list of about 120 bacterial isolates from injured human skin in Example 1 (“the list in Example 1”); and/or (b) one or more of the Staphylococcus aureus strain in Table 6
6. The composition of any one of the paragraphs 1-5, wherein at least 80 or 100 different strains of Staphylococcus aureus from the list in Example 1 and Table 6, and/or at least 20 or 25 different MLSTs of Staphylococcus aureus from the list in
7. The composition of any one of paragraphs 1-6, comprising at least three different strains of isolated bacteriophages, each capable of infecting a bacteria of the species Staphylococcus aureus, wherein each of said at least three different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical (e.g., in the combined coding region) to one of the nucleic acid sequence as set forth in SEQ ID NOs: 1-7, wherein said at least three different strains of isolated bacteriophages in combination target (i) at least 100 different strains of Staphylococcus aureus from the list in Example 1 and Table 6; and/or (ii) at least 25 different MLSTs of Staphylococcus aureus from the list in
8. The composition of any one of paragraphs 1-7, comprising at least three different strains of isolated bacteriophages, each capable of infecting a bacteria of the species Staphylococcus aureus, wherein each of said at least three different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical (e.g., in the combined coding region) to one of the nucleic acid sequence as set forth in SEQ ID NOs: 1-7, wherein (i) at least 90 different strains of Staphylococcus aureus from the list in Example 1 and Table 6, and/or (ii) at least 25 different MLSTs of Staphylococcus aureus from the list in
9. The composition of any one of paragraphs 1-8, wherein at least one bacteriophage of said at least two different strains of isolated bacteriophages is genetically modified such that (a) the genome thereof comprises a heterologous sequence; and/or (b) a transposable element (TE) thereof is inactive; optionally, said TE is inactivated by a mutation (e.g., deletion) that inactivates (a) a transposase of the TE, and/or (b) a structural element of the TE required for transposition.
10. The composition of paragraph 9, wherein (a) said heterologous sequence encodes a therapeutic agent or a diagnostic agent; and/or (b) said transposable element is any one listed in Table 7.
11. The composition of any one of paragraphs 1-10, comprising no more than 10, e.g., no more than 7, different bacteriophage strains.
12. The composition of any one of paragraphs 1-11, being formulated for topical delivery, oral delivery, rectal delivery or delivery by inhalation.
13. A recombinant bacteriophage capable of infecting bacteria of the species Staphylococcus aureus, wherein said bacteriophage has a genomic nucleic acid sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical (e.g., in the combined coding region) to one of the nucleic acid sequences as set forth in SEQ ID NOs: 1-7, and wherein said bacteriophage is genetically modified such that the genome thereof comprises a heterologous sequence; and/or lacks a native transposon sequence present in said bacteriophage prior to said bacteriophage is genetically modified.
14. The recombinant bacteriophage of paragraph 13, wherein said heterologous sequence encodes a therapeutic agent or a diagnostic agent.
15. The recombinant bacteriophage of paragraph 14, or the composition of paragraph 10, wherein said therapeutic agent comprises an immune modulating agent.
16. A pharmaceutical composition comprising the recombinant bacteriophage of any one of paragraph 13-15 as the active agent, and a pharmaceutical carrier.
17. The pharmaceutical composition of paragraph 16, being formulated for topical delivery, oral delivery, rectal delivery or delivery by inhalation.
18. An isolated bacteriophage capable of (lytically) infecting bacteria of the species Staphylococcus aureus (e.g., Staphylococcus aureus present in an Atopic Dermatitis patient), wherein said bacteriophage has a genomic nucleic acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical (e.g., in the combined coding region) to one of the nucleic acid sequences as set forth in SEQ ID NOs: 1-7.
19. A method of treating a disease associated with a Staphylococcus aureus infection in a subject in need thereof (e.g., a subject having Atopic Dermatitis), comprising administering to the subject a therapeutically effective amount of a composition comprising at least one isolated bacteriophage strain capable of infecting bacteria of the species Staphylococcus aureus causing the infection, wherein said at least one bacteriophage strain has a genomic nucleic acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical (e.g., in the combined coding region) to one of the nucleic acid sequences set forth in SEQ ID NOs: 1-7, thereby treating the disease associated with a Staphylococcus aureus infection.
20. A method of treating a disease (e.g., Atopic Dermatitis) associated with a Staphylococcus aureus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the composition of any one of paragraphs 1-12, thereby treating the disease associated with a Staphylococcus aureus infection.
21. The method of paragraph 19 or 20, wherein the disease is Atopic Dermatitis (AD); or the disease is further associated with or characterized by Staphylococcus epidermidis infection.
22. The method of any one of paragraphs 19-21, wherein said administering comprises topically administering, orally administering or rectally administering.
23. The method of any one of paragraphs 19-22, wherein said composition comprises no more than 7 different bacteriophage strains.
24. The method of any one of paragraphs 19-23, further comprising identifying the strain of Staphylococcus aureus colonizing the subject prior to the administering.
25 The method of any one of paragraphs 19-24, wherein said at least one bacteriophage strain is genetically modified such that (a) the genome thereof comprises a heterologous sequence; and/or (b) the genome thereof either comprises inactive or lacks transposable elements.
26. The method of paragraph 25, wherein said heterologous sequence encodes a therapeutic agent or a diagnostic agent.
27. The method of paragraph 26, wherein said therapeutic agent comprises an immune modulating agent.
28. The method of any one of paragraphs 19-27, wherein the subject has been treated with, or is to be further treated with an antibiotic effective against Staphylococcus aureus (e.g., Staphylococcus aureus present in an Atopic Dermatitis patient).
29. The method of any one of paragraphs 19-27, further comprising treating the subject with an antibiotic effective against Staphylococcus aureus (e.g., Staphylococcus aureus present in an Atopic Dermatitis patient).
It should be understood that any one embodiment of the invention described herein, including those described only in the examples or claims, or numbered paragraphs herein, can be combined with any one or more additional embodiments of the invention, unless such combination is improper or expressly disclaimed.
Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.
In the drawings:
The present invention, in some embodiments thereof, relates to bacteriophage strains capable of infecting bacteria of the genus Staphylococcus and more particularly bacteria of the species Staphylococcus aureus.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.
The present inventors have isolated novel bacteriophage strains characterized by having a high specificity to one or more Staphylococcus aureus strains. The disclosed bacteriophage are lytic, and as such do not have any capacity to integrate into the DNA of their bacterial host. Such bacteriophages bring about immediate target bacterial eradication through lysis after hijacking the host protein expression machinery to manufacture needed phage protein components.
The present inventors sought to combine particular phage strains and provide them as a cocktail which is capable of lysing a myriad of Staphylococcus aureus strains in a single dose. The cocktails can serve as an off-the-shelf therapeutic for the treatment of Atopic dermatitis (AD), which is known to be associated with Staphylococcus aureus infections. Furthermore, it is envisaged that the cocktails will have high therapeutic efficacy for treating AD at the individual level, since each individual can be infected by a wide range of Staphylococcus aureus strains.
The combinations disclosed herein are typically synergistic (e.g., synergistic combination) with respect to their inhibitory effect on the target bacteria. This may be quantitated by measuring the time taken to mutation (TTM), i.e., the time taken for a bacteria to mutate and overcome the inhibitory effect of a phage. When two phages X and Y are known to infect a target bacteria strain H, the TTM of each phage separately as well as the TTM of their combination is measured under same growth conditions. The synergistic redundancy effect appears when the TTM of combination [X, Y] is longer than that of both X and Y.
In certain embodiments, the at least two different strains of isolated bacteriophages have synergistic redundancy effect, based on time-to-mutant (TTM) that is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 80% above the longest individual phage TTM with respect to the bacteria using which the TTM is measured.
Alternatively, or in addition, in certain embodiments, the at least two different strains of isolated bacteriophages have synergistic redundancy effect, based on normalized area under the curve for OD600-time plot (AUC) that is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% smaller than the smallest individual phage normalized area under the curve with respect to said bacteria (or a mixture of more than one of said bacteria).
Here, when the bacterial growth in the presence of a bacteriophage (or combination thereof) is plotted as OD600 over time, an area under the curve can be calculated for each phage (or combination thereof). Such AUC, when normalized against no phage control AUC, can be compared to assess synergistic suppression of bacteria growth by phage combinations as compared to individual phages in the combination.
Without being bound to theory, the synergy may be derived from different mechanism of infection used by the two phages X and Y. According to certain embodiments of the present invention, the synergic TTM increase may be predicted by the “at least 2 phage % coverage,” and/or the “at least 3 phage % coverage,” and/or the “at least 4 phage % coverage,” and/or the “at least 5 phage % coverage” trait of a phage combination.
Thus, according to a first aspect of the present invention, there is provided an isolated bacteriophage capable of infecting bacteria of the species Staphylococcus aureus, wherein the bacteriophage has a genomic nucleic acid sequence at least 95% identical to one of the nucleic acid sequences as set forth in SEQ ID NOs: 1-7. Optionally, the bacteriophage is not naturally existing and comprises at least one heterologous engineered mutation.
As used herein, the term “bacteriophage” and “phage” are used interchangeably and refer to an isolated virus that is capable of infecting a bacterium. Typically, a phage will be characterized by: 1) the nature of the nucleic acids that make up its genome, e.g., DNA, RNA, single-stranded or double-stranded; 2) the nature of its infectivity, e.g., lytic or temperate; and 3) the particular Staphylococcus aureus subspecies that it infects (and in certain instances the particular strain of that Staphylococcus aureus subspecies). This aspect is known as “host range.”
As used herein, the phrases “isolated bacteriophage,” “isolate” or grammatical equivalents refer to a bacteriophage which is removed from its natural environment (e.g. removed from bacteria which it typically infects). In one embodiment, the isolated bacteriophage is removed from cellular material and/or other elements that naturally exist in the source clinical or environmental sample. The term isolated bacteriophages includes such phages isolated from human or animal patients (“clinical isolates” or “clinical variants”) and such phages isolated from the environment (“environmental isolates”).
In one embodiment, the bacteriophages are lytic.
The term “lytic bacteriophage” refers to a bacteriophage that infects a bacterial host and causes that host to lyse without incorporating the phage nucleic acids into the host genome. A lytic bacteriophage is typically not capable of reproducing using the lysogenic cycle.
As used herein, the phrase “phage strain” refers to the deposited or sequenced phage, as described herein.
The bacteriophage and certain infected host bacteria have been deposited at the Polish Collection of micororganisms PCM), Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Ul. Weigla 12, 53-114 Wroclaw, Poland with the deposit numbers provided in Table 2.1 and Table 6, herein below.
The term “Staphylococcus aureus” relates to a species of bacteria of the Staphylococcus genus. Staphylococcus bacterium are Gram-positive bacteria in the family Staphylococcaceae from the order Bacillales. Under the microscope, they appear spherical (cocci), and form in grape-like clusters. Staphylococcus species are facultative anacrobic organisms (capable of growth both aerobically and anaerobically). It will be appreciated that the term “Staphylococcus aureus” includes bacteria that are currently classified or will be reclassified as Staphylococcus aureus bacteria.
Exemplary strains of Staphylococcus aureus that are infected by the phage strains of the present invention are those that are found in human specimens (e.g., skin, intact or damaged such in burns, and wounds).
In some embodiments, the bacteriophages provided herein are capable of lysing deleterious Staphylococcus aureus bacteria that induce immune and/or inflammatory response(s).
In a particular embodiment, the phages described herein are capable of infecting at least one, two, three, four, five, six, seven, eight, nine or more Staphylococcus aureus strains (e.g. from the list in Example 1 and/or table 6) that infect a subject (e.g. AD patient) and/or at least one, two, three, four, five, six, seven, eight, nine or more CCs of Staphylococcus aureus from the list in
In a particular embodiment, the phages described herein are capable of infecting at least one, two, three, four, five, six, seven, eight, nine or more Staphylococcus aureus strains (e.g. from the list in Example 1 and/or table 6) that infect a subject (e.g. AD patient) and/or at least one, two, three, four, five, six, seven, eight, nine or more CCs of Staphylococcus aureus from the list in
In a particular embodiment, the phages described herein are capable of infecting at least one, two, three, four, five, six, seven, eight, nine or more Staphylococcus aureus strains (e.g. from the list in Example 1 and/or table 6) that infect a subject (e.g. AD patient) and/or at least one, two, three, four, five, six, seven, eight, nine or more CCs of Staphylococcus aureus from the list in
According to a particular embodiment, the phages described herein are capable of infecting Staphylococcus aureus bacterial strains having a specific capsule locus type.
Also contemplated are progeny of the phages having a genomic nucleic acid as set forth in SEQ ID NOs: 1-7, wherein the progeny is capable of infecting the same subspecies (or even strain) of Staphylococcus aureus as that the parent bacteriophage having one of the above set forth genomic nucleic acid sequence infects. Such progeny may have genomes having a sequence at least 85% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, 96% identical, 97% identical 98% identical, or 99% identical to the genome of the parent bacteriophage.
As used herein, the term “or progeny of the bacteriophage” refers to bacteriophages stemming from or derived from the strains identified herein.
Also contemplated are functional homologs of those that have a genomic nucleic acid sequence as set forth in SEQ ID NOs: 1-7, wherein the functionally homologous bacteriophage is capable of infecting essentially the same subspecies (or even strain) of Staphylococcus aureus as that which the bacteriophage having one of the above set forth genomic nucleic acid sequence infects.
As used herein “functional homolog” or “functionally homologous” or “variant” or grammatical equivalents as used herein refer to a bacteriophage with a genomic nucleic acid sequence different than that of the sequenced bacteriophage (i.e., at least one mutation) resulting in a bacteriophage that is endowed with substantially the same ensemble of biological activities (+/−10%, 20%, 40%, 50%, 60% when tested under the same conditions) as that of the sequenced bacteriophage and can be classified as infecting essentially the same strain or subspecies of bacteria based on known methods of species/strain classifications.
A bacteriophage “infects” bacteria if it either causes the bacteria to lyse or integrates its nucleic acid sequence into the bacterial genome.
According to a particular embodiment, the bacteriophage disclosed herein lyse their target bacteria.
According to a particular embodiment, the bacteriophage capability to infect (also termed “to target”) their target bacteria is measured using a solid assay or a liquid assay.
According to some embodiments, the genomic nucleic acid sequence of the bacteriophages described herein is at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96% least about 97%, at least about 97.1%, at least about 97.2%, at least about 97.3%, at least about 97.4%, at least about 97.5%, at least about 97.6%, at least about 97.7%, at least about 97.8%, at least about 97.9%, at least about 98%, at least about 98.1%, at least about 98.2%, at least about 98.3%, at least about 98.4%, at least about 98.5%, at least about 98.6%, at least about 98.7%, at least about 98.8%, at least about 98.9%, at least about 99%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, at least about 99.8%, at least about 99.9%, at least about 99.95% 99.95%, at least about 99.99%, or more identical to the (i) genomic sequence of the genomic sequences as set forth in SEQ ID NOs: 1, 2, 3, 4, 5, 6 or 7; and/or (ii) combined region of the essential genes of a bacteriophage selected from the bacteriophages listed in Table 2, as set forth in Example 7.
In particular, the bacteriophage has a genomic nucleic acid sequence at least 95% identical (% homologous) to the nucleic acid sequence as set forth in SEQ ID NOs: 1, 2, 3, 4, 5, 6 or 7; and/or (ii) combined region of the essential genes of a bacteriophage selected from the bacteriophages listed in Table 2, as set forth in Example 7.
According to a specific embodiment, the bacteriophage has a genomic nucleic acid sequence at least 95% identical (% homologous) to the full length nucleic acid sequence as set forth in SEQ ID NOs: 1, 2, 3, 4, 5, 6 or 7.
According to a specific embodiment, the bacteriophage comprises at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical genes (e.g., in the combined region) to the essential genes of a bacteriophage selected from the bacteriophages listed in Table 2, wherein the essential genes are genes as set forth for the selected bacteriophage in Example 7.
As used herein, “percent homology,” “percent identity,” “sequence identity” or “identity” or grammatical equivalents as used herein in the context of two nucleic acid or polypeptide sequences includes reference to the residues in the two sequences which are the same when aligned. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g. charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences which differ by such conservative substitutions are considered to have “sequence similarity” or “similarity.” Means for making this adjustment are well-known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., according to the algorithm of Henikoff S and Henikoff J G. [Amino acid substitution matrices from protein blocks. Proc. Natl. Acad. Sci. U.S.A. 1992, 89 (22): 10915-9].
Percent identity can be determined using any homology comparison software, including for example, the BlastN software of the National Center of Biotechnology Information (NCBI) such as by using default parameters.
Other exemplary sequence alignment programs that may be used to determine % homology or identity between two sequences include, but are not limited to, the FASTA package (including rigorous (SSEARCH, LALIGN, GGSEARCH and GLSEARCH) and heuristic (FASTA, FASTX/Y, TFASTX/Y and FASTS/M/F) algorithms, the EMBOSS package (Needle, stretcher, water and matcher), the BLAST programs (including, but not limited to BLASTN, BLASTX, TBLASTX, BLASTP, TBLASTN), megablast and BLAT. In some embodiments, the sequence alignment program is BLASTN. For example, 95% homology refers to 95% sequence identity determined by BLASTN, by combining all non-overlapping alignment segments (BLAST HSPs), summing their numbers of identical matches and dividing this sum with the length of the shorter sequence.
In some embodiments, the sequence alignment program is a basic local alignment program, e.g., BLAST. In some embodiments, the sequence alignment program is a pairwise global alignment program. In some embodiments, the pairwise global alignment program is used for protein-protein alignments. In some embodiments, the pairwise global alignment program is Needle. In some embodiments, the sequence alignment program is a multiple alignment program. In some embodiments, the multiple alignment program is MAFFT. In some embodiments, the sequence alignment program is a whole genome alignment program. In some embodiments, the whole genome alignment is performed using BLASTN. In some embodiments, BLASTN is utilized without any changes to the default parameters.
According to some embodiments of the invention, the identity is a global identity, i.e., an identity over the entire nucleic acid sequences of the invention and not over portions thereof.
According to an additional or alternative embodiment, a functional homolog is determined as the average nucleotide identity (ANI), which detects the DNA conservation of the core genome (Konstantinidis K and Tiedje J M, 2005, Proc. Natl. Acad. Sci. USA 102:2567-2592). In some embodiments, the ANI between the functional homolog and the deposited bacteriophage (or that having a genome as set forth in any one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7 is of at least about 95%, at least about, 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.1%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, at least about 99.9% or more.
According to an additional or alternative embodiment, a functional homolog is determined by the degree of relatedness between the functional homolog and the bacteriophage having a genome as set forth in any one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7 determined as the Tetranucleotide Signature Frequency Correlation Coefficient, which is based on oligonucleotide frequencies (Bohlin J. et al. 2008, BMC Genomics, 9:104). In some embodiments, the Tetranucleotide Signature Frequency Correlation coefficient between the variant and the bacteriophage having a genome as set forth in any one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7 is of about 0.99, 0.999 or more.
According to an additional or alternative embodiment, the degree of relatedness between the functional homolog and the bacteriophage having a genome as set forth in any one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7 is determined as the degree of similarity obtained when analyzing the genomes of the parent and of the variant bacteriophage by Pulsed-field gel electrophoresis (PFGE) using one or more restriction endonucleases. The degree of similarity obtained by PFGE can be measured by the Dice similarity coefficient. In some embodiments, the Dice similarity coefficient between the variant and the bacteriophage having a genome as set forth in any one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7 is of at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.1%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, at least about 99.9% or more.
According to an additional or alternative embodiment, the degree of relatedness between the functional homolog and the bacteriophage having a genome as set forth in any one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7 is determined by the Pearson correlation coefficient obtained by comparing the genetic profiles of both phages obtained by repetitive extragenic palindromic element-based PCR (REP-PCR) (see e.g. Chou and Wang, Int J Food Microbiol. 2006, 110:135-48). In some embodiments, the Pearson correlation coefficient obtained by comparing the REP-PCR profiles of the variant and the above described (e.g. deposited phage) is of at least about 0.99, at least about 0.999 or more-see for example bmcmicrobioldotbiomedcentraldotcom/articles/10.1186/s12866-020-01770-2.
According to an additional or alternative embodiment, the degree of relatedness between the functional homolog and the bacteriophage having a genome as set forth in any one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7 is defined by the linkage distance obtained by comparing the genetic profiles of both phages obtained by Multi-locus sequence typing (MLST) (see e.g. Maiden, M. C., 1998, Proc. Natl. Acad. Sci. USA 95:3140-3145). In some embodiments, the linkage distance obtained by MLST of the functional homolog and the phage having a genome as set forth in any one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7 is of at least about 0.99, at least about 0.999 or more.
According to an additional or alternative embodiment, the functional homolog comprises a functionally conserved gene or a fragment thereof (i.e. an essential gene) e.g., an integrase gene, a polymerase gene, a capsid protein assembly gene, a DNA terminase, a tail fiber gene, or a repressor gene that is at least about 97%, at least about 98%, at least about 99%, at least about 99.1%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, at least about 99.9%, or more identical to that of the bacteriophage having a genome as set forth in any one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7.
For each of the disclosed bacteriophages, Example 7 provides the gene name of their essential genes.
According to an additional or alternative embodiment, the functional homolog is defined by a comparison of the coding sequence (gene) order.
According to an additional or alternative embodiment, the functional homolog is defined by a comparison of the coding sequence (gene) order of the essential genes of a bacteriophage selected from the bacteriophages listed in Table 2, as set forth in Example 7.
According to an additional or alternative embodiment, the functional homolog is defined by a comparison of order of non-coding sequences.
According to an additional or alternative embodiment, the functional homolog is defined by a comparison of order of coding and non-coding sequences.
According to some embodiments of the invention, the combined coding region of the functional homolog is such that it maintains the original order of the coding regions as within the genomic sequence of the bacteriophage having a genome as set forth in any one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7, yet without the non-coding regions. In certain embodiments, the combined coding region does not include (excludes) transposon sequences, such as a sequence required for transposition, and/or transposon enzyme coding sequences (such as Transposase coding sequence).
For example, in case the genomic sequence has the following coding regions, A, B, C, D, E, F, G, each flanked by non-coding sequences (e.g., regulatory elements, and the like), the combined coding region will include a single nucleic acid sequence having the A+B+C+D+E+F+G coding regions combined together while maintaining the original order of their genome, yet without the non-coding sequences.
According to some embodiments of the invention, the combined non-coding region of the functional homolog is such that it maintains the original order of the non-coding regions as within the genomic sequence of the bacteriophage having a genome as set forth in any one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7, yet without the coding regions as originally present in the original bacteriophage.
According to some embodiments of the invention, the combined non-coding region and coding region (i.e., the genome) of the functional homolog is such that it maintains the original order of the coding and non-coding regions as within the genomic sequence of the bacteriophage having a genome as set forth in any one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7.
As used herein “maintains” relate to at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of the coding and/or non-coding regions of the functional homolog compared to the bacteriophage having a genome as set forth in any one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7.
According to an additional or alternative embodiment, the functional homolog is defined by a comparison of gene content.
According to a specific embodiment, the functional homolog comprises a combined coding region at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more (e.g., 100%) identical to the combined coding region existing in genome of the bacteriophage having a genome as set forth in any one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7.
As used herein “combined coding region” refers to a nucleic acid sequence including all of the coding regions of the original bacteriophage yet without the non-coding regions of the original bacteriophage.
In one embodiment, the bacteriophages show up to 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with the bacteriophages disclosed herein and share at least one of the following characteristics-similar host range; similar type of infectivity (i.e. lytic or temperate).
In another embodiment, the bacteriophages show up to 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with the bacteriophages disclosed herein and share both of the following characteristics-similar host range; similar type of infectivity.
Additional bioinformatics methods that may be used to determine relatedness between two phage genomes include Nucmer and Minimap, both of which are alignment based tools; Win-zip, Jacard distance and MinHash, each of which are information based tools; and Codon usage similarity, pathway similarity and protein motif similarity.
As used herein, “host range” refers to the bacteria that are susceptible to infection by a particular phage. The host range of a phage may include, but is not limited to, a strain, a subspecies, a species, a genus, or multiple genera of bacteria.
Phage isolates may be prepared and phenotyped using methods known in the art, e.g., a plaque assay, liquid media assay, solid media assay. In some embodiments, the solid media assays to quantify and isolate phage are based on plaque assays (S. T. Abedon et al., Methods in Molecular Biology 2009 (Clifton, N.J.), 501, 161-74), ranging from efficiency of plating (EOP) (E. Kutter, Methods in Molecular Biology 2009 (Clifton, N.J.), 501, 141-9) to spot testing (P. Hyman et al., Advances in Applied Microbiology (1st ed., Vol. 70, pp. 217-48) 2010. Elsevier Inc.). In some embodiments, the plate format used for the plaque assay can be modified, e.g., from a petri dish to a 48-well plate.
In some embodiments, a double-layer plaque assay is used to phenotype bacteriophage isolates. For example, a starter culture of 4 mL BHIS may be inoculated with 50-100 colonies from a plate. This culture may be incubated at 37° C. for 16 hours in an anaerobic environment. A volume of 200 μL of this culture may be mixed with 100 μL of a phage-containing sample (or medium only control) and incubated for 15 minutes. 5 mL of BHIS top agar (pre-molten 0.4% agar BHIS supplemented with 1 mM Ca2+, Mn2+ and Mg2+ ions may be added), and the mixture may be poured over a BHIS bottom agar plate (1.5% agar BHIS). The plates may be allowed to gel at room temperature, and then incubated for 16 hours at 37 or 32° C. (for simulating skin temperature) in anaerobic environment until plaques are identified.
In some embodiments, a modified spot drop assay is used to phenotype bacteriophage isolates. For example, a starter culture of 4 mL BHIS may be inoculated with 50-100 colonies from a plate. This culture may be incubated at 37° C. for 16 hours in an anaerobic environment. A volume of 200 μL of this culture may be mixed with 5 mL of BHIS top agar (pre-molten 0.4% agar BHIS supplemented with 1 mM Ca2+, Mn2+ and Mg2+ ions may be added), and the mixture may be poured over a BHIS bottom agar plate (1.5% agar BHIS). The plates may be allowed to gel at room temperature, and then incubated for 30 min at 37 C in anaerobic environment. At this stage, 5 μL of samples containing phage or media only as control may be dropped on the plate, left to absorb, and then may be incubated for 16 hours until plaques are visible for counting.
In some embodiments, inverted Plaque Assay is used as an alternative to the Double Layer Plaque Assay. In this method, phages are incorporated into the top agar, the top agar is poured on half of the media plate and bacteria are streaked on it. Contrary to the double layer plaque assay, no plaque is formed, but rather, sensitive bacteria appeared either as infected lawn (perforated lawn), or single colonies, or no colony at all only at the part of the plate which consist of top agar and phages. The growth of bacteria on the top agar with the tested phage is compared to the growth of the same bacteria on the other side of the plate, without phage (No Phage Control (NPC)).
Each phage is diluted to 109 PFU/mL in BHIS, and 10 μL is transferred into 10 mL melted top agar with 1 mM ions (at 56° C.). Following a gentle mix, the tube contents is poured onto a BHIS plate. The plates are left for 20 min to allow the top agar to solidify. Frozen bacteria is inoculate on agar plate, and incubated overnight (15-16 h) at 37° C. The following day, 5-10 colonies are merged and streaked on the inverted plate, starting with the NPC side and ending in the top agar with phage side. The plates are incubated at 37° C. overnight (15-16 hours). The growth of the bacteria on the top agar and phage side is compared to the growth on the bacteria on the NPC side. Bacteria are designated sensitive (“S”) or resistant (“R”) to the phage.
In some embodiments, a liquid media assay is used to phenotype the bacteriophage. In some embodiments, liquid-based phage infection assays follow the time-course of infection and can provide more than quantitative end-points of infection as compared to the solid-phase plaque assays. In some embodiments, by mixing phage with bacteria in liquid medium, then following the turbidity of the culture over time, one can discern finer differences (e.g., a delay in the time of cell lysis) between how different bacterial strains interact with the phage.
In some embodiments, a liquid-based phage infection assays is used to measure the time duration from the beginning of the experiment, when the bacteria and phages are mixed together until the host bacteria develops resistance to the phages (presumably by mutation). This period is also known as time-to-mutant (TTM). Such TTM assay was used to produce the results presented in
In some embodiments, the TTM is declared synergistic when the OD reading reaches a predetermined threshold (e.g. 0.3 OD600). Then synergistic redundancy effect is concluded if the TTM of a combination (e.g. X, Y) is for example 50% longer than the longer TTM of the individual member phages (e.g., the TTM of X by itself and the TTM of Y by itself).
In one embodiment, the synergistic effect is defined as above 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% above the longer individual phage member TTM.
In some embodiments, the liquid media assay allows for high-throughput measurements by using 96-well plates and reading optical density in a plate reader. For example, a bacterial strain may be grown for 16 hours until an OD600 of about 1.5-2. This culture may then be diluted using BHIS medium to a starting optical density, typically between 0.03 and 0.05 OD600. A volume of 200 μL of culture may then be dispensed into the wells of a Nunclon flat-bottomed 96-well plate. 10 μL of a sample containing phage or 10 μL of medium as control may be added to each well. The wells may be covered with 50 μL of mineral oil to limit evaporation, and a thin sterile optically transparent polyurethane film may be added to keep the culture sterile. Optical density measurements may be carried out every 20 minutes, e.g., in a Tecan Infinite M200 plate reader connected to a Tecan EVO75 robot. Between measurements, the plate may be incubated while shaking at 37 or 32° C., e.g., inside the EVO75 incubator.
In some embodiments, infectivity is determined by the plaque presence in a solid assay only. In some embodiments, infectivity is determined by the plaque presence in a liquid assay only. In some embodiments, infectivity is determined by the plaque presence in both the liquid assay and the solid assay.
The bacteriophages described herein are typically present in a preparation in which their prevalence (i.e., concentration) is enriched over that (exceeds that) found in nature.
The term “preparation” refers to a composition in which the prevalence of bacteriophage is enriched over that found in nature. Since bacteriophages infect bacterial cells, they may be found in specimens or samples which are rich in bacteria—e.g. environmental samples such as sewage, wastewater and biological samples including feces. According to some embodiments of the invention, the preparation comprises less than 50 microbial species, e.g., bacteria and fungi—e.g., less than 40 bacterial species, less than 30 bacterial species, less than 20 bacterial species, less than 10 bacterial species, less than 5 bacterial species, less than 4 bacterial species, less than 3 bacterial species, less than 2 bacterial species or even devoid completely of bacteria.
According to a particular embodiment, the preparation comprises a single strain of bacteriophage (or a functional homolog thereof), no more than two different bacteriophage strains (or functional homologs thereof), no more than three different bacteriophage strains (or functional homologs thereof), no more than four different bacteriophage strains (or functional homologs thereof), no more than five different bacteriophage strains (or functional homologs thereof), no more than six different bacteriophage strains (or functional homologs thereof), no more than seven different bacteriophage strains (or functional homologs thereof), no more than eight different bacteriophage strains (or functional homologs thereof), no more than nine different bacteriophage strains (or functional homologs thereof), or no more than ten different bacteriophage strains (or functional homologs thereof).
In one embodiment, the preparation comprises a plurality of phage strains when at least one of the phage strains is STA48-1 (having the genome sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to the sequence as set forth in SEQ ID NO: 1).
In another embodiment, the preparation comprises a plurality of phage strains when at least one of the phage strains is STA48-7 (having the genome sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to the sequence as set forth in SEQ ID NO: 7).
In another embodiment, the preparation comprises a plurality of phage strains when at least one of the phage strains is STA48-5 (having the genome sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to the sequence as set forth in SEQ ID NO: 5).
In one embodiment, the preparation comprises at least two different phage strains when at least one of the phage strains is STA48-1 (having the genome sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to the sequence as set forth in SEQ ID NO: 1) and the other of the phage strains is STA48-7 (having the genome sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to the sequence as set forth in SEQ ID NO: 7).
In one embodiment, the preparation comprises at least three different phage strains when at least one of the phage strains is STA48-1 (having the genome sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to the sequence as set forth in SEQ ID NO: 1), the second of the phage strains is STA48-7 (having the genome sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to the sequence as set forth in SEQ ID NO: 7) and the third of the phage strains is STA48-5 (having the genome sequence at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8%, 99.9% or 100%) identical to the sequence as set forth in SEQ ID NO: 5).
Exemplary combinations of core phages in a single composition are provided in Table 1 herein below.
Additional contemplated combinations are provided in Example 2, Example 3 and Example 4 herein below.
One exemplary cocktail contemplated by the present inventors is one which comprises the following phages: STA48-1, STA48-7, STA48-5 (ADX2).
In one embodiment, the combination is selected such that more than 20% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g., comprising more than 70 different Staphylococcus aureus strains, more than 90 different Staphylococcus aureus strains and preferably more than 110 different Staphylococcus aureus strains) are targeted (and lysed). In one embodiment, the combination is selected such that more than 20% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed. In a specific embodiment, the mixed population is selected from the list Staphylococcus aureus strains in Example 1 and/or Table 6.
In another embodiment, the combination is selected such that at least 40, 60, 80, 100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 different Staphylococcus aureus strains are targeted.
In one embodiment, the combination is selected such that more than 30% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted (and lysed). In one embodiment, the combination is selected such that more than 30% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed.
In one embodiment, the combination is selected such that more than 40% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted (and lysed). In one embodiment, the combination is selected such that more than 40% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed.
In one embodiment, the combination is selected such that more than 45% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted (and lysed). In one embodiment, the combination is selected such that more than 45% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed.
In one embodiment, the combination is selected such that more than 50% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted (and lysed). In one embodiment, the combination is selected such that more than 50% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed.
In one embodiment, the combination is selected such that more than 55% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted (and lysed). In one embodiment, the combination is selected such that more than 55% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed.
In one embodiment, the combination is selected such that more than 60% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted (and lysed). In one embodiment, the combination is selected such that more than 60% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed.
In one embodiment, the combination is selected such that more than 65% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted (and lysed). In one embodiment, the combination is selected such that more than 65% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed.
In one embodiment, the combination is selected such that more than 70% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted (and lysed). In one embodiment, the combination is selected such that more than 70% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed.
In one embodiment, the combination is selected such that more than 75% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted (and lysed). In one embodiment, the combination is selected such that more than 75% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed.
In one embodiment, the combination is selected such that more than 80% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted (and lysed). In one embodiment, the combination is selected such that more than 80% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed.
In one embodiment, the combination is selected such that more than 85% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted (and lysed). In one embodiment, the combination is selected such that more than 85% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed.
In one embodiment, the combination is selected such that more than 90% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted (and lysed). In one embodiment, the combination is selected such that more than 90% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed.
The combinations described herein can be selected to include phages which have overlapping host coverages. The host coverages can be defined in terms of bacterial strain classification, bacterial capsule type, bacterial clonal complex and/or Multi-locus sequence typing (MLST)—see (sanger-pathogens(dot)github(dot)io/ariba/).
In one embodiment, the combination is selected such that more than 10% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination). In one embodiment, the combination is selected such that more than 10% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination).
In another embodiment, the combination is selected such that at least 10, 20, 40, 60, 80, 100 specific Staphylococcus aureus strains are targeted by more than 1 (e.g. 2, 3, 4 or 5) phage strain of the combination.
In another embodiment, the combination is selected such that more than 15% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination). In one embodiment, the combination is selected such that more than 15% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination).
In another embodiment, the combination is selected such that more than 20% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination). In one embodiment, the combination is selected such that more than 20% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination).
In another embodiment, the combination is selected such that more than 25% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination). In one embodiment, the combination is selected such that more than 25% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination).
In another embodiment, the combination is selected such that more than 30% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination). In one embodiment, the combination is selected such that more than 30% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination).
In another embodiment, the combination is selected such that more than 35% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination). In one embodiment, the combination is selected such that more than 35% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination).
In another embodiment, the combination is selected such that more than 40% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination). In one embodiment, the combination is selected such that more than 40% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination).
In another embodiment, the combination is selected such that more than 45% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination). In one embodiment, the combination is selected such that more than 45% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination).
In another embodiment, the combination is selected such that more than 50% of the different strains of bacteria of a mixed population of Staphylococcus aureus (e.g. comprising more than 80 different Staphylococcus aureus strains, more than 100 different Staphylococcus aureus strains and preferably more than 120 different Pseudomonas aureus strains) are targeted by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination). In one embodiment, the combination is selected such that more than 50% of all the strains of Staphylococcus aureus which infect humans are targeted and lysed by more than one phage strain (e.g. at least 2 phage strains of the combination, at least 3 phage strains of the combination, at least 4 phage strains of the combination or at least 5 phage strains of the combination).
It will be appreciated that, throughout the specification, when a phage is specifically named, the present invention also considers those phage that have at least 90% identity to the sequence of their genome, wherein the phage has a similar host range.
According to a specific embodiment, the preparation comprises at least about 106 PFU, 107 PFU, 108 PFU, 109 PFU, or even 1010 PFU or more of the above described (e.g. deposited) bacteriophages or functional homolog of same or progeny of same.
The bacteriophages described herein may be genetically modified such that their genomes include a heterologous sequence.
In one embodiment, the heterologous sequence serves as a marker signifying whether transformation is successful—e.g., a barcode sequence.
In another embodiment, the heterologous sequence encodes a therapeutic or diagnostic agent (also referred to herein as a payload). The therapeutic or diagnostic agent may be a nucleic acid (e.g. RNA silencing agent), a peptide or a protein. The therapeutic agent is typically selected according to the disease which is to be treated. Thus, for example if the bacteriophage is to be used for treating diseases associated with Staphylococcus aureus infection, the therapeutic agent is typically one that is known to be useful for treating that disease.
As used herein, the term “RNA silencing agent” refers to an RNA which is capable of specifically inhibiting or “silencing” the expression of a target gene. In certain embodiments, the RNA silencing agent is capable of preventing complete processing (e.g., the full translation and/or expression) of an mRNA molecule through a post-transcriptional silencing mechanism. RNA silencing agents include noncoding RNA molecules, for example RNA duplexes comprising paired strands, as well as precursor RNAs from which such small non-coding RNAs can be generated. Exemplary RNA silencing agents include dsRNAs such as siRNAs, miRNAs and shRNAs. In one embodiment, the RNA silencing agent is capable of inducing RNA interference. In another embodiment, the RNA silencing agent is capable of mediating translational repression. According to an embodiment of the invention, the RNA silencing agent is specific to the target RNA and does not cross inhibit or silence a gene or a splice variant which exhibits 99% or less global homology to the target gene, e.g., less than 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% global homology to the target gene.
Exemplary RNA silencing agents include but are not limited to siRNA, shRNA, miRNA and guide RNA (gRNA).
The therapeutic agent may be a bacterial protein or peptide (e.g., a small bacterial peptide that could act as a vaccine in the subject treated with the bacteriophage), a therapeutic protein or peptide (e.g., a cytokine, e.g., IL-15), a soluble peptide or protein ligand (e.g., a STING agonist or TRAIL), an antibody or an antibody fragment that recognizes a virulent or disease-causing antigen or is useful in an immunotherapy (e.g., a checkpoint inhibitor), an enzyme that when expressed produces a therapeutic useful product (e.g., a bacterial enzyme or metabolic cassette that produces a therapeutically useful bacterial metabolite or other bacterial antigen; a bacterial enzyme that produces LPS or causes cleavage of LPS from the outer membrane of gram negative bacteria), a shared tumor antigen or an enzyme that when expressed produces a shared tumor antigen, a unique tumor antigen or neoantigen or an enzyme that when expressed produces a unique tumor antigen or neoantigen.
In another embodiment, the therapeutic agent is an agent that is therapeutic in the treatment of atopic dermatitis.
According to another embodiment, the therapeutic agent is an immune modulating agent.
Examples of immune modulating agents include immunomodulatory cytokines, including but not limited to, IL-2, IL-15, IL-7, IL-21, GM-CSF as well as any other cytokines that are capable of further enhancing immune responses; immunomodulatory antibodies, including but not limited to, anti-CTLA4, anti-CD40, anti-41BB, anti-OX40, anti-PD1 and anti-PDL1.
Examples of diagnostic agents include fluorescent proteins or enzymes producing a colorimetric reaction. Exemplary proteins that generate a detectable signal include, but are not limited to green fluorescent protein (Genbank Accession No. AAL33912), alkaline phosphatase (Genbank Accession No. AAK73766), peroxidase (Genbank Accession No. NP_568674), histidine tag (Genbank Accession No. AAK09208), Myc tag (Genbank Accession No. AF329457), biotin ligase tag (Genbank Accession No. NP_561589), orange fluorescent protein (Genbank Accession No. AAL33917), beta galactosidase (Genbank Accession No. NM_125776), Fluorescein isothiocyanate (Genbank Accession No. AAF22695) and strepavidin (Genbank Accession No. S11540).
In another example, the diagnostic agent is a luminescent protein such as products of bacterial luciferase genes, e.g., the luciferase genes encoded by Vibrio harveyi, Vibrio fischeri, and Xenorhabdus luminescens, the firefly luciferase gene FFlux, and the like.
Recombinant methods for inserting heterologous sequences into a phage genome are well-known in the art. The appropriate coding sequence is inserted in one or more of several locations in the phage genome. In one embodiment, the nucleic acid insert that is introduced into the phage genome is approximately no more than 10% of the phage genome length.
The payload coding sequence is inserted either after early, middle or late expressing phage genes and it can be expressed as part of a phage operon, relying on either an existing phage operon, promoter and terminator, or as a distinct operon. In the latter case, a relevant promoter and terminator from the phage is inserted as part of the newly formed operon.
For example, if strong expression of a payload is required, the payload coding sequence is added after the stop codon of the major capsid protein and expressed as part of the major capsid operon. Alternatively, it can be expressed by addition of a major capsid protein promoter and terminator as an individual newly formed operon which can be inserted anywhere in the phage genome that would not damage the functionality of the phage. If low expression of a payload is desired, the payload coding sequence can be added after the terminase gene (or other low expressing gene), which usually has low expression. Moreover, payload levels are tuned by adding a ribosome binding site with a desired strength.
In order to avoid negatively affecting phage infectivity and specificity, the payload coding sequence is typically not inserted inside an existing phage open reading frame. An exception to this is the case when the payload is intended to be expressed as a fusion protein of the phage outer coat. In that latter case of payload display, the payload coding sequence is added in frame to sequence encoding the phage coat protein.
The bacteriophages described herein may be used to treat subjects having diseases associated with Staphylococcus aureus infection.
Diseases associated with Staphylococcus aureus infection include atopic dermatitis and infectious wounds.
As used herein, the term “subject” includes mammals, preferably human beings at any age which suffer from the pathology. Those in need of treatment may include individuals already having AD, as well as those at risk of having, or who may ultimately acquire the disease. The need for treatment is assessed, e.g., by the presence of one or more risk factors associated with the development of AD, the presence or progression of AD, or likely receptiveness to treatment of a subject having AD. For example, “treating” AD may encompass reducing or eliminating associated symptoms, and does not necessarily encompass the elimination of the underlying disease etiology, e.g., a genetic instability locus.
The term “treating” refers to inhibiting, preventing, or arresting the development of a pathology (disease, disorder or condition) and/or causing the reduction, remission, or regression of a pathology. Those of skill in the art will understand that various methodologies and assays can be used to assess the development of a pathology, and similarly, various methodologies and assays may be used to assess the reduction, remission, or regression of a pathology.
The bacteriophage may be used per se or as part of a pharmaceutical composition, where it is mixed with suitable carriers or excipients.
As used herein a “pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
Herein the term “active ingredient” refers to the bacteriophage accountable for the biological effect.
Hereinafter, the phrases “physiologically acceptable carrier” and “pharmaceutically acceptable carrier” which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
Herein the term “excipient” refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
Techniques for formulation and administration of drugs may be found in “Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.
Suitable routes of administration may, for example, include topical, inhalation (e.g., by inhaler or nebulizer), oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, intraperitoneal, intranasal, or intraocular injections.
Alternately, one may administer the pharmaceutical composition in a local rather than systemic manner, for example, via topical application to the skin. In one embodiment, the bacteriophage may be administered directly into a tumor of the subject.
Pharmaceutical compositions of some embodiments of the invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, spray drying, coating or lyophilizing processes.
Pharmaceutical compositions for use in accordance with some embodiments of the invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
In some embodiments, the composition is formulated for delivery to mammalian skin, mammalian eyes, mammalian teeth or an implant to be inserted into a mammal. Preferably, the mammal is a human.
In some embodiments, the composition is formulated for topical application. In some embodiments, the composition is in the form of a gel, cream, ointment, lotion, paste, solution, microemulsion, liquid wash, spray, application stick, cosmetic, dressing, face-wash, soap, powder, spray, capsule, eye drop, eye ointment, eye lotion, solid, or a moist sponge wipe, or is bonded to a solid surface. In some embodiments, the composition comprises an adjuvant, a carrier or a vehicle. In some embodiments, the composition comprises one or more additives selected from solubilizers, emollients, humectants, thickening agents, permeation enhancers, chelating agents, antioxidants, buffering agents, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives. In some embodiments, the composition comprises one or more of a gel-forming agent, a cream-forming agent, a wax, an oil, a surfactant, and a binder.
“Administering” or “administration of” a substance, a compound, a composition, a formulation or an agent to a subject can be carried out using one of a variety of methods known to those skilled in the art. For example, a compound or an agent can be administered topically, by applying on the skin, teeth, eyes or on parts of eyes including but not limited to the lens capsule and the corneal stroma. For example, the composition may be in a form suitable for topical administration and be in the form of a cream, paste, solution, powder, spray, aerosol, capsule, eye drop, eye ointment, eye lotion, solid or gel, or may be bonded to a solid surface. The composition may also form part of a face wash, soap, application stick, cosmetic or dressing. Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods. In some aspects, the administration includes both direct administration, including self-administration, and indirect administration, including the act of prescribing a formulation. For example, as used herein, a physician who instructs a patient to self-administer a formulation, or to have the formulation administered by another and/or who provides a patient with a prescription for a formulation is administering the formulation to the patient.
The pharmaceutical compositions described herein may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into compositions for pharmaceutical use. Methods of formulating pharmaceutical compositions are known in the art (see, e.g., “Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, PA). In some embodiments, the pharmaceutical compositions are subjected to appropriate formulation for topical administration, including but not limited to methods of manufacturing a gel, cream, paste, ointment, solution, microemulsion, lotion, liquid wash, spray, application stick, cosmetic, dressing, face-wash, soap, powder, spray, capsule, eye drop, eye ointment, eye lotion, solid, a moist sponge wipe or a composition bonded to a solid surface.
The bacteriophage described herein may be formulated into pharmaceutical compositions in any suitable topical dosage form (e.g., a gel, cream, paste, ointment, solution, microemulsion, lotion, liquid wash, spray, application stick, cosmetic, dressing, face-wash, soap, powder, spray, capsule, eye drop, eye ointment, eye lotion, solid, a moist sponge wipe or may be bonded to a solid surface) and for any suitable type of administration (e.g., immediate-release, pulsatile-release, delayed-release, extended-release or sustained release). In some embodiments, the bacteriophages are formulated for administration as a gel, cream, paste, ointment, solution, microemulsion, lotion, liquid wash, spray, application stick, cosmetic, dressing, face-wash, soap, powder, spray, capsule, eye drop, eye ointment, eye lotion, solid, a moist sponge wipe or may be bonded to a solid surface. The composition may be administered once or more daily, weekly, or monthly.
In some embodiments, the bacteriophage may be covalently attached to a carrier particle, for use as a topical formulation or for application to an implant. In some embodiments, the carrier particle is typically approximately spherical, may have an average diameter of up to 20 microns, up to 15 microns, up to 10 microns, from 0.1 microns, from 0.5 microns or any combinations of these—e.g. from 0.1 microns to 20 microns or from 0.5 microns to 10 microns. The particles in general can be approximately round or spheroid; they are preferably smooth, especially for use on sensitive parts of the body. Particle size is suitably measured using methods and apparatus recognized as standard in the art. Particle sizing in dispersions can be accomplished using a variety of techniques, including laser diffraction, dynamic light scattering (DLS), disc centrifugation, and light microscopy. Examples of sizing equipment are made by Malvern Instruments (UK), using laser diffraction methods. In some embodiments, bacteriophages may be covalently attached to a plurality of particles. These are preferably in relatively homogenous form, in which a large proportion of the plurality of particles have diameters of up to 20 microns, up to 15 microns, up to 10 microns, from 0.1 microns, from 0.5 microns or any combinations of these—e.g. from 0.1 microns to 20 microns or from 0.5 microns to 10 microns. In some embodiments, 80% or more, 90% or more or 95% or more of the particles with phage covalently attached have diameters of up to 20 microns, up to 15 microns, up to 10 microns, from 0.1 microns, from 0.5 microns or any combinations of these—e.g. from 0.1 microns to 20 microns or from 0.5 microns to 10 microns. WO2015118150 describes further the carrier particle that may be used for the bacteriophage formulation.
Particles for use in the application to which bacteriophage are immobilized by covalent bonding are generally substantially inert to the animal to be treated. In examples, nylon particles (beads) were used. Other inert, preferably non-toxic biocompatible material may be used. In addition, the particle may be made of a biodegradable material. Suitable materials include polymethyl methacrylate, polyethylene, ethylene/acrylate copolymer, nylon-12, polyurethane, silicone resin, silica and nylon 1010. WO2003093462 describes further materials that the particles may be made from.
Immobilization or attachment of bacteriophage to the particle substrate may be achieved by covalent bonds formed between the bacteriophage coat protein and the carrier substrate. Bacteriophage may also be immobilized to the substrate via their head, tail, or capsule by activating the substrate particle before the addition and bonding of bacteriophage. The term “activated/activating/activation” refers to the activation of the substrate such as electrically, e.g. by corona discharge, or by reacting said substrate with various chemical groups (leaving a surface chemistry able to bind viruses, such as bacteriophage head, tail or capsule group). WO2015118150, WO2003093462 and WO2007072049 describe further the activation of said substrate, coupling of phage to substrate, and details of methods for covalent attachment of phage to particles.
In some embodiments, the bacteriophage is formulated for delivery to mammalian skin, eyes, teeth, or implant. In some embodiments, the composition comprises the bacteriophage and a pharmaceutically or cosmetically acceptable excipient, wherein the bacteriophage and the excipient do not occur together in nature. In some embodiments, the composition comprises the bacteriophage and a pharmaceutically or cosmetically acceptable excipient, wherein the excipient is a non-naturally occurring excipient. In some embodiments, the composition comprises the bacteriophage encapsulated in a pharmaceutically or cosmetically acceptable polymer, wherein the polymer is a non-naturally occurring polymer. In some embodiments, the composition described herein may be encapsulated to facilitate a longer shelf life and storage of phage to ensure reproducible dosages, and to facilitate effective delivery to the desired site of action or adsorption. In some embodiments, the composition may be encapsulated in emulsions, ointments, polymeric or lipid microparticles (microspheres & microcrystals), nanoparticles, nanofibers, microfibers, membranes, thin film structures and/or liposomes. Natural and synthetic polymers may be used for phage encapsulation. Phage encapsulation may be performed using a variety of hydrophilic and hydrophobic polymers including but not limited to agarose, alginate, chitosan, pectin, whey protein, gelled milk protein, hyaluronic acid methacrylate, hydroxypropyl methyl cellulose (HPMC), poly (N-isopropylacrylamide), Poly (DL-lactide: glycolide), polyesteramide, polyvinyl pyrrolidone, polyethylene oxide/polyvinyl alcohol, cellulose diacetate, and/or polymethyl methacrylate. Examples of the materials that could be used for preparation of phages encapsulated in liposomes include, but are not limited to, phosphatidylcholine, cholesterol, Softisan 100™; soybean phosphatidylcholine, DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine), DOPS (1,2-diolcoyl-sn-glycero-3-phospho-L-serine), DLPC (1,2-Dilauroyl-sn-glycero-3-phosphorylcholine), Cholesterol-PEG 600, and/or cholesteryl esters. Solid-liquid particles for topical administration can be produced by solid lipids and adjuvants including, but not limited to, surfactants and emulsifiers, e.g., stearic acid, oleic acid, tripalmitin, cetyl alcohol, cetyl palmitate, tristearin, trimyristin, and hydrogenated vegetable fat (HVF), glyceryl behenate, glyceryl monostearate, glyceryl palmitostearate, glyceryl tripalmitate, sodium taurocholate, octadecyl alcohol, Tween 80, Poloxamer 188, Compritol® 888 ATO, Imwitor® 900, Precirol® ATO5, carnauba wax and isodecyl oleate, hydrogenate phosphatidylcholine, cholesterol. Malik et al., 2017; Bacteriophages Methods and Protocols 2018; and Das and Chaudhury, 2011 describe further materials and techniques for bacteriophage encapsulation.
In some embodiments, the composition is in single dosage form. Single dosage forms may be in a liquid, gel or cream form. Single dosage forms may be administered directly to a patient without modification or may be diluted or reconstituted prior to administration. Single dosage forms of the composition may be prepared by portioning the composition into smaller aliquots, single dose containers, single dose liquid forms, or single dose solid forms, such as tablets, granulates, nanoparticles, nanocapsules, microcapsules, microtablets, pellets, or powders. A single dose in a solid form may be reconstituted by adding liquid, typically sterile water or saline solution, or mixing with other dermal formulation components, prior to administration to a patient.
Dosage regimens may be adjusted to provide a therapeutic response. Dosing can depend on several factors, including severity and responsiveness of the disease, route of administration, time course of treatment (days to months to years), and time to amelioration of the condition. For example, a single bolus may be administered at one time, several divided doses may be administered over a predetermined period of time, or the dose may be reduced or increased as indicated by the therapeutic situation.
In some embodiments, the ingredients are supplied either separately or mixed together in unit dosage form. The pharmaceutical compositions may be packaged in a hermetically sealed container such as an ampoule or sachet indicating the quantity of the agent. In some embodiment, one or more of the pharmaceutical compositions is supplied as a dry sterilized lyophilized powder or water-free concentrate in a hermetically sealed container and can be reconstituted (e.g., with water or saline) to the appropriate concentration for administration to a subject. In some embodiments, one or more of the prophylactic or therapeutic agents or pharmaceutical compositions is supplied as a dry sterile lyophilized powder in a hermetically sealed container and reconstituted prior to administration. In some embodiments, the dry sterilized lyophilized powder is produced by spray-drying and can include a mixture of one of the following: 30-50% dextran, 40-70% sucrose, 0.5-2% tris, and 1-3% leucin; or 30-50% hydroxyethyl starch, 40-70% sucrose, 0.5-2% tris, and 1-3% leucine. Cryoprotectants can be included for a lyophilized dosage form, principally 0-10% sucrose (optimally 0.5-1.0%). Other suitable cryoprotectants include trehalose and lactose. Other suitable bulking agents include glycine and arginine, either of which can be included at a concentration of 0-0.05%, and polysorbate-80 (optimally included at a concentration of 0.005-0.01%). Additional surfactants include but are not limited to polysorbate 20 and BRIJ surfactants.
For injection, the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
For oral administration, the pharmaceutical composition can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
Pharmaceutical compositions which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.
For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
For administration by nasal inhalation, the active ingredients for use according to some embodiments of the invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
The pharmaceutical composition described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.
Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.
The pharmaceutical composition of some embodiments of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
Pharmaceutical compositions suitable for use in context of some embodiments of the invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients (bacteriophage) effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., inflammatory bowel disease) or prolong the survival of the subject being treated.
Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays. For example, a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.
In some embodiments, the composition is delivered to a subject in need thereof so as to provide one or more bacteriophage in an amount corresponding to a multiplicity of infection (MOI) of about 1 to about 10. MOI is determined by assessing the approximate bacterial load in the site of infection, or using an estimate for a given type of disease and then providing phage in an amount calculated to give the desired MOI.
In some embodiments, MOI may be selected based on the “multiplicity of 10 rule,” which states that where there are on average in order of 10 phages adsorbed per bacterium, bacterial density reduces significantly (Abedon S T, 2009, Foodborne Pathog Dis 6:807-815; and Kasman L M, et al., 2002, J Virol 76:5557-5564); whereas lower-titer phage administration (e.g., using a MOI lower than 10) is unlikely to be successful (Goode D, et al., 2003, App Environ Microbiol 69:5032-5036; Kumari S, et al., 2010, J Infect Dev Ctries 4:367-377).
In other embodiments, the amount of phage (or combination of phages) is provided so as to reduce the amount of bacteria (e.g. Staphylococcus aureus) present on a defined size area of the skin by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even 100%.
In certain embodiments, the bacteriophage described herein is administered to ameliorate at least one manifestation of atopic dermatitis (AD) in a subject and results in one or more symptoms or physical parameters of the condition or disorder to improve by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or more as compared to levels in an untreated or control subject. In some embodiments, the improvement is measured by comparing the symptom or physical parameter in a subject prior to and following administration of the bacteriophage. In some embodiments, the measurable physical parameter is a reduction in bacterial colony-forming unit (CFU) count or plaque-forming unit (PFU) count from a skin sample or blood sample of the subject.
Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in “The Pharmacological Basis of Therapeutics,” Ch. 1 p.1).
Dosage amount and interval may be adjusted individually to provide levels of the active ingredient are sufficient to induce or suppress the biological effect (minimal effective concentration, MEC). The MEC will vary for each preparation but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.
Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.
The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.
Compositions of some embodiments of the invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as is further detailed above.
Compositions described herein may comprise more than one phage strain. In one embodiment, the composition comprises 2 phage strains, 3 phage strains, 4 phage strains, 5 phage strains or more.
In one embodiment, the bacteriophage cocktails comprise a plurality of phages that target a single Staphylococcus aureus strain.
In one embodiment, the bacteriophage cocktails comprise a plurality of phages that target more than one Staphylococcus aureus strain.
Examples of particular combinations of phages are provided herein below.
The pharmaceutical compositions of the present invention also may be combined with one or more non-phage therapeutic and/or prophylactic agents, useful for the treatment and/or prevention of bacterial infections, as described herein and/or known in the art (e.g. one or more traditional antibiotic agents). Other therapeutic and/or prophylactic agents that may be used in combination with the phage(s) or phage product(s) of the invention include, but are not limited to, antibiotic agents, anti-inflammatory agents, antiviral agents, antifungal agents, or local anesthetic agents.
Standard or traditional antibiotic agents that can be administered with the bacteriophages described herein include, but are not limited to, amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, rhodostreptomycin, streptomycin, tobramycin, apramycin, rifamycin, naphthomycin, mupirocin, geldanamycin, ansamitocin, carbacephems, imipenem, meropenem, ertapenem, faropenem, doripenem, panipenem/betamipron, biapenem, PZ-601, cephalosporins, cefacetrile, cefadroxil, cefalexin, cefaloglycin, cefalonium, cefaloridine, cefalotin, cefapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefradine, cefroxadine, ceftezole, cefaclor, cefonicid, cefprozil, cefuroxime, cefuzonam, cefmetazole, cefotetan, cefoxitin, cefcapene, cefdaloxime, cefdinir, cefditoren, cefetamet, cefixime, cefmenoxime, cefteram, ceftibuten, ceftiofur, ceftiolene, ceftizoxime, ceftriaxone, cefoperazone, ceftazidime latamoxef, cefclidine, cefepime, cefluprenam, cefoselis, cefozopran, cefpirome, cefquinome, flomoxef. ceftobiprole, azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, aztreonam, pencillin and penicillin derivatives, actinomycin, bacitracin, colistin, polymyxin B, cinoxacin, flumequine, nalidixic acid, oxolinic acid, piromidic acid, pipemidic acid, rosoxacin, ciprofloxacin, enoxacin, fleroxacin, lomefloxacin, nadifloxacin, norfloxacin, ofloxacin, pefloxacin, rufloxacin, balofloxacin, gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, pazufloxacin, sparfloxacin, temafloxacin, tosufloxacin, clinafloxacin, garenoxacin, gemifloxacin, stifloxacin, trovalfloxacin, prulifloxacin, acetazolamide, benzolamide, bumetanide, celecoxib, chlorthalidone, clopamide, dichlorphenamide, dorzolamide, ethoxyzolamide, furosemide, hydrochlorothiazide, indapamide, mafendide, mefruside, metolazone, probenecid, sulfacetamide, sulfadimethoxine, sulfadoxine, sulfanilamides, sulfamethoxazole, sulfasalazine, sultiame, sumatriptan, xipamide, tetracycline, chlortetracycline, oxytetracycline, doxycycline, lymecycline, meclocycline, methacycline, minocycline, rolitetracycline, methicillin, nafcillin, oxacilin, cloxacillin, vancomycin, teicoplanin, clindamycin, co-trimoxazole, flucloxacillin, dicloxacillin, ampicillin, amoxicillin and any combination thereof.
Standard antifungal agents include amphotericin B such as liposomal amphotericin B and non-liposomal amphotericin B.
The present inventors further contemplate administering to the subject a probiotic which comprises “good” bacteria to occupy the niche left by the reduced “negative” bacteria. Such probiotic bacteria may comprise lactobacillus, saccharomyces boulardii, and/or Bifidobacterium.
The bacteiophages and bacteriophage cocktails of the invention can be used in anti-infective compositions for controlling the growth of bacteria, in particular Staphylococcus aureus, to prevent or reduce the incidence of nosocomial infections. The anti-infective compositions find use in reducing or inhibiting colonization or growth of bacterial on a surface contacted therewith. The bacteriophages of the invention may be incorporated into compositions that are formulated for application to biological surfaces, such as the skin and mucus membranes, as well as for application to non-biological surfaces.
Anti-infective formulations for use on biological surfaces include, but are not limited to, gels, creams, ointments, sprays, and the like. In particular embodiments, the anti-infective formulation is used to sterilize a surgical field, or the hands and/or exposed skin of healthcare workers and/or patients.
Anti-infective formulations for use on non-biological surfaces include sprays, solutions, suspensions, wipes impregnated with a solution or suspension and the like. In particular embodiments, the anti-infective formulation is used on solid surfaces in hospitals, nursing homes, ambulances, etc., including, e.g., appliances, countertops, and medical devices, hospital equipment. In preferred embodiments, the non-biological surface is a surface of a hospital apparatus or piece of hospital equipment. In particularly preferred embodiments, the non-biological surface is a surgical apparatus or piece of surgical equipment.
The present invention also encompasses diagnostic methods for determining the causative agent at the site of the bacterial infection. In certain embodiments, the diagnosis of the causative agent of a bacterial infection is performed by (i) culturing a sample from a patient, e.g., a skin sample, a tumor biopsy, stool sample or other sample appropriate for culturing the bacteria causing the infection; (ii) contacting the culture with one or more bacteriophages of the invention; and (iii) monitoring for evidence of cell growth and/or lysis of the culture. Because the activity of phages tends to be species or strain specific, susceptibility, or lack of susceptibility, to one or more phages of the invention can indicate the species or strain of bacteria causing the infection.
The sample may be a tissue biopsy or swab collected from the patient, or a fluid sample, such as blood, tears, or urine.
As used herein the term “about” refers to +10%.
The terms “comprises,” “comprising,” “includes,” “including,” “having” and their conjugates mean “including but not limited to.”
The term “consisting of” means “including and limited to.”
The term “consisting essentially of” means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
As used herein, the singular form “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof.
Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
As used herein the term “method” refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
When reference is made to particular sequence listings, such reference is to be understood to also encompass sequences that substantially correspond to its complementary sequence as including minor sequence variations, resulting from, e.g., sequencing errors, cloning errors, or other alterations resulting in base substitution, base deletion or base addition, provided that the frequency of such variations is less than 1 in 50 nucleotides, alternatively, less than 1 in 100 nucleotides, alternatively, less than 1 in 200 nucleotides, alternatively, less than 1 in 500 nucleotides, alternatively, less than 1 in 1000 nucleotides, alternatively, less than 1 in 5,000 nucleotides, alternatively, less than 1 in 10,000 nucleotides.
It is understood that any Sequence Identification Number (SEQ ID NO) disclosed in the instant application can refer to either a DNA sequence or a RNA sequence, depending on the context where that SEQ ID NO is mentioned, even if that SEQ ID NO is expressed only in a DNA sequence format or a RNA sequence format. Similarly, though some sequences are expressed in a RNA sequence format (e.g., reciting U for uracil), depending on the actual type of molecule being described, it can refer to either the sequence of a RNA molecule comprising a dsRNA, or the sequence of a DNA molecule that corresponds to the RNA sequence shown. In any event, both DNA and RNA molecules having the sequences disclosed with any substitutes are envisioned.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments unless the embodiment is inoperative without those elements.
Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.
Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non-limiting fashion.
Generally, the nomenclature used herein, and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, “Molecular Cloning: A laboratory Manual” Sambrook et al., (1989); “Current Protocols in Molecular Biology” Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., “Current Protocols in Molecular Biology,” John Wiley and Sons, Baltimore, Maryland (1989); Perbal, “A Practical Guide to Molecular Cloning,” John Wiley & Sons, New York (1988); Watson et al., “Recombinant DNA,” Scientific American Books, New York; Birren et al. (eds) “Genome Analysis: A Laboratory Manual Series,” Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; “Cell Biology: A Laboratory Handbook,” Volumes I-III Cellis, J. E., ed. (1994); “Culture of Animal Cells-A Manual of Basic Technique” by Freshney, Wiley-Liss, N. Y. (1994), Third Edition; “Current Protocols in Immunology” Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), “Basic and Clinical Immunology” (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), “Selected Methods in Cellular Immunology,” W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; “Oligonucleotide Synthesis” Gait, M. J., ed. (1984); “Nucleic Acid Hybridization” Hames, B. D., and Higgins S. J., eds. (1985); “Transcription and Translation” Hames, B. D., and Higgins S. J., eds. (1984); “Animal Cell Culture” Freshney, R. I., ed. (1986); “Immobilized Cells and Enzymes” IRL Press, (1986); “A Practical Guide to Molecular Cloning” Perbal, B., (1984) and “Methods in Enzymology” Vol. 1-317, Academic Press; “PCR Protocols: A Guide To Methods And Applications,” Academic Press, San Diego, CA (1990); Marshak et al., “Strategies for Protein Purification and Characterization-A Laboratory Course Manual” CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.
An assembly of 120 bacterial isolates from injured human skin were obtained from ATCC, CCUG, BEI and IMHA bacterial repositories, and used for isolation of infecting phage: ATCC-HFH-30676, ATCC-NCTC 9318, BEI-HFH-29568, BEI-MRSA131, BEI-Sal263, BEI-Sa1303, BEI-SA1912, CCUG-10778, CCUG-17417, CCUG-30188 B, CCUG-35603, CCUG-38604, CCUG-47207, CCUG-49255, CCUG-56450, CCUG-60578, CCUG-68145, CCUG-7410, IHMA-2162980, IHMA-2163579, IHMA-2163598, IHMA-2163653, IHMA-2163681, IHMA-2163703, IHMA-2163709, IHMA-2163714, IHMA-2163719, IHMA-2164168, IHMA-2164169, IHMA-2164172, IHMA-2164173, IHMA-2164174, IHMA-2164178, IHMA-2164182, IHMA-2164188, IHMA-2164189, IHMA-2164190, IHMA-2164192, IHMA-2164194, IHMA-2164195, IHMA-2164196, IHMA-2164197, IHMA-2164201, IHMA-2164204, IHMA-2164205, IHMA-2164206, IHMA-2213861, IHMA-2213869, IHMA-2213905, IHMA-2213907, IHMA-2213918, IHMA-2213948, IHMA-2213965, IHMA-2213976, IHMA-2213985, IHMA-2213993, IHMA-2214003, IHMA-2221107, IHMA-2221108, IHMA-2221113, IHMA-2221115, IHMA-2221118, IHMA-2221119, IHMA-2221120, IHMA-2221124, MEI 40523500v.1 IHMA-2221125, IHMA-2221127, IHMA-2244260, IHMA-2244261, IHMA-2244269, IHMA-2244289, IHMA-2244311, IHMA-2244333, IHMA-2250008, IHMA-2262230, IHMA-2262285, IHMA-2262338, IHMA-2262342, IHMA-2262346, IHMA-2262355, IHMA-2262366, IHMA-2262373, IHMA-2262388, IHMA-2262396, IHMA-2262404, IHMA-2262410, IHMA-2262411, IHMA-2262414, IHMA-2262417, IHMA-2262418, IHMA-2262425, IHMA-2262426, IHMA-2262427, IHMA-2281017, IHMA-2281018, IHMA-2281019, IHMA-2281020, IHMA-2281021, IHMA-2281022, IHMA-2281024, IHMA-2281026, IHMA-2281027, IHMA-2281030, IHMA-2281031, IHMA-2311520, IHMA-2311525, IHMA-2311527, IHMA-2311529, IHMA-2311531, IHMA-2311535, IHMA-2311536, IHMA-2311547, IHMA-2311548, IHMA-2311549, IHMA-2311550, IHMA-2311552, IHMA-2311553, IHMA-2311568, and IHMA-2311588.
The isolates are well distributed across the Staphylococcus aureus phylogenetic trcc (
Phage were amplified from liquid broth or from soft agar double agar overlay plaque. Amplification from liquid broth was performed by diluting 50 μL of isolated phage sample at MOI 0.01 into 4 mL log phase host culture at OD=0.05, and incubating at 37 or 32° C. (mimicking skin temperature) overnight. When amplified from a plaque, a whole plaque was picked using a 1 μL loop and release the plaque into the culture OD600=0.05. Tubes were centrifuged, the supernatant was filtered by 0.45 μm filter, and 1 mM of the divalent ions Ca2+ and Mg2+ were added.
Phage titers were determined by drop plaque assay as follows: host culture was prepared by inoculating 4 mL liquid BHIS with 5-10 colonies of the host and incubating at 37° C., until OD was 2 (16 hrs). 150 μL of host culture were added to 4 mL of molten top agar (BHIS top agar: BHIS media, 0.4% Agarose) with divalent ions Ca2+ and Mg2+ and dispensed on BHIS agar plats (1.6% Agarose). Plates were left to solidify for 15 min at RT before incubating the plate at 37° C. for 30 minutes. Then dilutions of phage sample were dropped (5 μL). Plates were incubated for overnight before counting plaques (10-50 plaques/drop) and determination of phage titer (number of plaques×200×reciprocal of counted dilution=PFU/mL).
Solid host range was performed in the same manner as detailed in the above section (“Phage isolation, amplification and determination of phage titers” section). Following plaques enumeration (10-50 plaques/drop) and determination of phage titer/host, the Efficiency of Plating (EOP) was calculated as:
For sensitive/resistant determination, EOP above 0.1 (EOP >0.1) entitled the corresponding bacteria sensitive to the respective phage. The % coverage was determined based on the number of sensitive bacteria that were found sensitive as percent of the number of bacterial strains tested.
Ten bacterial colonies of each tested strain were picked and transferred into a culture tube prefilled with 4 mL of liquid BHIS. Cultures were incubated to OD600≥1.5 by shaking, 180 rpm, at 37° C. for overnight (15-16 h). Bacterial cultures were diluted using BHIS supplemented with 1 mM MMC ions to reach a final OD600 of 0.05 and dispensed into a 96-well plate. Each phage was diluted to a concentration of 10
For host range determination, a bacterial strain was defined as sensitive with respect to a phage if a decrease in OD600 values was observed (OD600<0.1) during the assay, even with mutants arising at the end of the assay.
For the assay assessing total clearance of the host, the same procedure as above was used except that the culture was left incubated for 24 h or 72 h at 37 or 32° C. Clearance was declared when the final OD600 was 0.2 or lower (also termed clearance threshold). No significance difference in host range was found between 37 and 32° C. The % coverage was determined based on the number of sensitive bacteria that were found sensitive as percent of the number of bacterial strains tested.
Staphylococcus aureus isolates from injured human skin were used to hunt phages. Phages were isolated from environmental samples (sewage), purified, and sequenced. Their taxonomy was deduced from the sequence based on International Committee on Taxonomy of Viruses (ICTV) classification (Table 2). Additionally, the sequence was used to determine the distance (sequence homology) between the phages (
Staphylococcus aureus species.
Kayvirus
Rosenblumvirus
Rosenblumvirus
Rosenblumvirus
Kayvirus
Kayvirus
Kayvirus
Staphylococcus aureus species.
Specifically, Phage STA48-1 was deposited on Dec. 6, 2021, at the Polish Collection of micororganisms PCM), Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Ul. Weigla 12, 53-114 Wroclaw, Poland, with accession number F/00170.
Phage STA48-2 was deposited on Dec. 6, 2021, at the Polish Collection of micororganisms PCM), Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Ul. Weigla 12, 53-114 Wroclaw, Poland, with accession number F/00171.
Phage STA48-3 was deposited on Dec. 6, 2021, at the Polish Collection of micororganisms PCM), Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Ul. Weigla 12, 53-114 Wroclaw, Poland, with accession number F/00172.
Phage STA48-4 was deposited on Dec. 6, 2021, at the Polish Collection of micororganisms PCM), Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Ul. Weigla 12, 53-114 Wroclaw, Poland, with accession number F/00173.
Phage STA48-5 was deposited on Dec. 6, 2021, at the Polish Collection of micororganisms PCM), Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Ul. Weigla 12, 53-114 Wroclaw, Poland, with accession number F/00174.
Phage STA48-6 was deposited on Dec. 6, 2021, at the Polish Collection of micororganisms PCM), Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Ul. Weigla 12, 53-114 Wroclaw, Poland, with accession number F/00175.
Phage STA48-7 was deposited on Dec. 6, 2021, at the Polish Collection of micororganisms PCM), Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Ul. Weigla 12, 53-114 Wroclaw, Poland with accession number F/00176.
The % sequence homology (based on local BLAST) of the isolated phages was compared as set forth in
The host ranges (HR) of the phages were tested. HR analysis of isolated phage was performed in solid assay as detailed above. The percent coverage of these isolated SA strains is summarized in Table 3, herein below.
The host range of phages STA48-1 and STA48-7 was also assessed in the liquid assay based on the bacterial targets assembly (119 isolates) described above and was found to be 87.4% and 65.5% respectively, based on the sensitivity threshold as described above.
The combination of four phages STA48-1, STA48-7, STA48-5 and STA48-4 was used for clearance performance assessment in liquid according to the assay described above, based on the bacterial targets assembly (119 isolates) described above and yielded 87% clearance, i.e., 87% of the tested host strains were cleared by the phage combination, based on the clearance threshold as described above.
The three combinations in Table 4 below were assessed in the liquid clearance assay, based on a subgroup of 22 host strains. The achieved % clearance is detailed in table 4.
The host range of the phage was also profiled according to the clonal complex of the infected bacteria. The results are set forth in
For this example, the particular phages are referred to by the single letter designation in Table 2, herein above.
2 phage combinations were analyzed in silico for their ability to lyse the 118 different strains of Staphylococcus aureus bacteria (as described for Example 1) based on the ability of the single phage to lyse the bacteria as assessed by a solid (EOP) assay. The alternative combinations sorted by the percentage number of infected bacterial strains are provided herein below. This trait is referred to as “at least 1 phage % coverage.” The number following each combination refers to the Percent trait performance—in this case the percent of the 119 strains that are targeted by the phage combination. The combinations are listed in descending performance grade.
Thus, for example, in the case of [ba;86], which provides the highest percent coverage of all the 2 phage combinations, STA48-4 and STA48-1 lysed 86% of all the strains of Staphylococcus aureus analyzed.
[ba;86] [cd;85] [da;85] [dg;85] [bc;85] [bg;84] [af;84] [cf;83] [bd;83] [ae;83] [ag;83] [ca; 82] [ge;81] [cc;81] [df;81] [de;80] [gf;80] [cg;79] [bf;65] [fe;59] [be;53].
The percent of host bacterial strains that are infected by two phages of a phage combination are provided. This trait is referred to as “at least 2 phage % coverage.” The phage combinations are ordered in descending performance grade.
Thus, for example, in the case of [ca;73], when STA48-5 and STA48-1 are used in a combination, 73% of the bacterial strains analyzed were targeted by both these phage.
[ca;73] [cg;70] [ag;69] [da;67] [cd;64] [dg;61] [ba;44] [bc;43] [bd;42] [bg;41] [be;39] [a e;36] [af;36] [ce;36] [cf;34] [de;34] [gf;34] [ge;32] [df;32] [bf;27] [fe;22].
3 Phage Combinations 3 phage combinations were analyzed in silico for their ability to lyse the 118 different strains of Staphylococcus aureus bacteria based on the ability of the single phage to lyse the bacteria as assessed by a solid (EOP) assay.
The combinations with their corresponding “at least 1 phage % coverage” are provided herein below. The number following each combination refers to the Percent trait performance. The phage combinations are ordered in descending performance grade. For example, in the case of [bdg;92], the combination that provided the highest percent coverage, STA48-4, STA48-7 and STA48-6 lysed 92% of all the strains of Staphylococcus aureus analyzed.
[bdg;92] [bcd;92] [bda;91] [dge;90] [bag;90] [cdf;90] [dgf;89] [cde;89] [bca;89] [baf;88] [dag;88] [daf;88] [dae;88] [bcg;87] [caf;87] [agf;87] [cda;87] [bcf;86] [bdf;86] [age;86] [bae;8 6] [cdg;86] [cae;86] [afe;86] [bce;85] [cgf;85] [bge;85] [bgf;85] [cfe;84] [cge;84] [dfe;84] [cag; 83] [bde;83] [gfe;83] [bfe;66].
The combinations with their corresponding “at least 2 phage % coverage” are provided herein below. The phage combinations are ordered in descending performance grade.
Thus, for example, in the case of [cag;78], when STA48-5, STA48-1 and STA48-6 are used in a combination, 78% of the bacterial strains analyzed were targeted by at least 2 of the 3 phages.
[cag;78] [cda; 77] [cdg;77] [dag;76] [cae;75] [bca;75] [caf;75] [age;75] [daf;74] [cge;74] [bag;74] [bcg;73] [bda;73] [agf;72] [cgf;72] [dae;71] [cdf;69] [bcd;69] [cde;68] [dgf;68] [bdg; 67] [dge;66] [bcf;60] [bgf;59] [baf;59] [bdf;56] [cfe;56] [afe;55] [gfe;54] [dfe;53] [bce;50] [bae; 50] [bde;50] [bge;49] [bfe;46].
The percent of host bacterial strains that are infected by three phages of a phage combination are provided. This trait is referred to as “at least 3 phage % coverage.” The phage combinations are ordered in descending performance grade.
Thus, for example, in the case of [cag;67], when STA48-5, STA48-1 and STA48-6 are used in a combination, 67% of the bacterial strains analyzed were targeted by each of the 3 phage.
[cag;67] [cda;64] [dag;60] [cdg;59] [bca;42] [bcg;41] [bda;40] [bag;40] [bcd;40] [bdg;3 8] [bae;35] [cae;35] [caf;34] [bce;34] [cgf;33] [agf;33] [cde;33] [dae;33] [cge;32] [bde;32] [bge; 31] [age;31] [daf;31] [cdf;31] [dge;31] [dgf;30] [baf;24] [bdf;22] [bcf;22] [bgf;21] [bfe;21] [afe; 19] [cfe; 18] [dfe; 18] [gfe; 17].
4 phage combinations were analyzed in silico for their ability to lyse the 118 different strains of Staphylococcus aureus bacteria based on the ability of the single phage to lyse the bacteria as assessed by a solid (EOP) assay.
The combinations with their corresponding “at least 1 phage % coverage” are provided herein below. The phage combinations are ordered in descending performance grade.
For example, in the case of [bdag;93], the 4 phage combination that provided the highest percent coverage, STA48-4, STA48-7, STA48-1 and STA48-6 lysed 93% of all the strains of Staphylococcus aureus analyzed.
[bdag;93] [bdgf;93] [bcdf;93] [bdaf;92] [bcdg;92] [bdge;92] [bcda;92] [bcde;92] [bdae; 91] [bagf;91] [dgfe;91] [bcaf;91] [dagf;91] [cdaf;91] [cdfe;91] [dage;91] [cdae;90] [bcag;90] [b age;90] [cdge;90] [cdgf;90] [dafe;90] [bcae;89] [cdag;88] [bafe;88] [cafe;88] [bcgf;88] [agfe;8 8] [cagf;87] [bcge;87] [bdfe;86] [bcfe;86] [cage;86] [bgfe;86] [cgfe;86].
The combinations with their corresponding “at least 2 phage % coverage” are provided herein below. The phage combinations are ordered in descending performance grade.
Thus, for example, in the case of [bdag;81], when STA48-4, STA48-7, STA48-1 and STA48-6 are used in a combination, 81% of the bacterial strains analyzed were targeted by at least 2 of the 4 phage.
[bdag;81] [bcda;81] [cagf;81] [dage;81] [dagf;81] [cdaf;81] [cdae;81] [cdgf;80] [cage;8 0] [bcdg;80] [cdag;80] [bcag;80] [bcge;79] [bcgf;79] [bcae;79] [cdge;79] [cgfe;79] [bcaf;79] [b age;78] [agfe;78] [cafe;78] [bagf;78] [bdae;76] [bdaf;76] [dafe;76] [cdfe;75] [bcdf;75] [dgfe;74] [bcde;74] [bdge;73] [bdgf;73] [bafe;62] [bcfe;62] [bgfe;62] [bdfe;60].
The combinations with their corresponding “at least 3 phage % coverage” are provided herein below. The phage combinations are ordered in descending performance grade.
Thus, for example, in the case of [cdag;75], when STA48-5, STA48-7, STA48-1 and STA48-6 are used in a combination, 75% of the bacterial strains analyzed were targeted by at least 3 of the 4 phage.
[cdag;75] [cage;71] [bcag;70] [cagf;68] [cdaf;67] [bcda;66] [cdae;65] [dagf;64] [bdag; 64] [cdgf;64] [cdge;64] [bcdg;64] [dage;64] [bcaf;56] [bdaf;55] [bagf;54] [bcdf;53] [bcgf;53] [c afe; 53] [bdgf;53] [dafe;50] [agfe;50] [cgfe;49] [cdfe;48] [bcae;47] [dgfe;47] [bdae;46] [bage;4 6] [bcde;45] [bcge;44] [bcfe;44] [bafe;43] [bdge;43] [bdfe;42] [bgfe;42].
The percent of host strains that are infected by 4 phages of phage combinations is provided herein below. This trait is referred to herein as “at least 4 phage % coverage.” Thus, for example, in the case of [cdag;57], when STA48-5, STA48-7, STA48-1 and STA48-6 are used in a combination, 57% of the bacterial strains tested were targeted by each of the four phage.
[cdag;57] [bcda;40] [bcag;40] [bdag;38] [bcdg;38] [cdae;33] [cagf;33] [bcae;33] [cage; 31] [bcge;31] [bcde;31] [bdae;31] [bage;31] [cdge;31] [cdaf;31] [dage;31] [cdgf;30] [dagf;30] [bdge;30] [bcaf;22] [bagf;21] [bcgf;21] [bdaf;20] [bcdf;20] [bdgf;19] [bafe; 19] [cafe; 18] [bcfe; 1 7] [bdfe;17] [cgfe; 17] [agfe; 17] [cdfe; 17] [dafe; 17] [bgfe; 16] [dgfe; 16].
5 phage combinations were analyzed in silico for their ability to lyse the 118 different strains of Staphylococcus aureus bacteria based on the ability of the single phage to lyse the bacteria as assessed by a solid (EOP) assay.
The combinations with their corresponding “at least 1 phage % coverage” are provided herein below. The number following each combination refers to the Percent trait performance—in this case the percent of the 119 strains that are targeted by the phage combination. The phage combinations are ordered in descending performance grade.
For example, in the case of [bdagf;94], the 5 phage combination that provided the highest percent coverage, STA48-4, STA48-7, STA48-1, STA48-6 and STA48-2 lysed 94% of all the strains of Staphylococcus aureus analyzed.
[bdagf; 94] [bcdaf;94] [bcdfe;93] [bdgfe;93] [bdage;93] [bcdag;93] [bcdgf;93] [bcdge; 92] [bdafe;92] [bcdac;92] [dagfe;92] [cdafe;92] [bcagf;91] [bcafe;91] [bagfe;91] [cdagf;91] [cd age;91] [cdgfe;91] [bcage;90] [bcgfe;88] [cagfe;88].
The combinations with their corresponding “at least 2 phage % coverage” are provided herein below. The phage combinations are ordered in descending performance grade.
Thus, for example, in the case of [bdagf; 84], when STA48-4, STA48-7, STA48-1, STA48-6 and STA48-2 are used in a combination, 84% of the bacterial strains tested were targeted by at least 2 of the 5 phage.
[bdagf;84] [dagfe;84] [cdgfe;84] [bdage;84] [cdagf;84] [bcdgf;84] [bcdge;84] [bcagf;8 4] [bcdae;84] [bcage;83] [cdafe;83] [bcdaf;83] [bcdag;83] [cagfe;83] [cdage;82] [bcgfe;81] [bc afe;80] [bagfe;80] [bdafe;78] [bdgfe;75] [bcdfe;75].
The combinations with their corresponding “at least 3 phage % coverage” are provided herein below. The phage combinations are ordered in descending performance grade.
Thus, for example, in the case of [cdage; 76], when STA48-5, STA48-7, STA48-1, STA48-6 and STA48-3 are used in a combination, 76% of the bacterial strains tested were targeted by at least 3 of the 5 phage.
[cdage; 76] [bcdag;76] [cdagf;75] [cagfe;73] [bcage; 73] [bcagf;72] [bcdaf;71] [cdafe;7 0] [bcdae;69] [dagfe;69] [bdage;69] [bdagf;69] [bcdgf;67] [cdgfe;67] [bcdge;66] [bcafe;60] [ba gfe;59] [bcdfe;59] [bcgfe;59] [bdafe;57] [bdgfe;57].
The combinations with their corresponding “at least 4 phage % coverage” are provided herein below. The phage combinations are ordered in descending performance grade.
Thus, for example, in the case of [cdagf;63], when STA48-5, STA48-7, STA48-1, STA48-6 and STA48-2 are used in a combination, 63% of the bacterial strains analyzed were targeted by at least 4 of the 5 phage.
[cdagf;63] [cdage;62] [bcdag;62] [bcagf;53] [bcdaf;52] [bdagf;51] [bcdgf;51] [cagfe;4 8] [cdafe;47] [dagfe;46] [cdgfe;46] [bcage;44] [bcdae;43] [bcdge;42] [bdage;42] [bcafe;41] [bd afe;40] [bagfe;39] [bcdfe;38] [bcgfe;38] [bdgfe;37].
For this example, the particular phages are referred to by the single letter designation in Table 2, herein above.
2 phage combinations were analyzed in silico for their ability to lyse the 118 different strains of Staphylococcus aureus bacteria as profiled by their clonal complex, based on the ability of the single phage to lyse a bacteria of a particular clonal complex as assessed by a solid (EOP) assay.
All the combinations below were found to cover 100% of the clonal complexes associated with the 119 bacterial strains. This trait is referred to as “at least 1 phage % coverage.” The number following each combination refers to the Percent trait performance—in this case the percent of bacteria strains as profiled by their clonal complex that are targeted by the phage combination.
[bc; 100] [bd; 100] [ba; 100] [bg; 100] [bf; 100] [be; 100] [cd; 100] [ca; 100] [cg; 100] [cf; 10 0] [ce; 100] [da; 100] [dg; 100] [df; 100] [de; 100] [ag; 100] [af; 100] [ae; 100] [gf; 100] [ge; 100] [fe; 100].
The percent of host bacterial strains (as profiled by their clonal complex) that are infected by two phages of a phage combination are provided. This trait is referred to as “at least 2 phage % coverage.” The phage combinations are ordered in descending performance grade.
[bc; 100] [cg;100] [ba; 100] [bg; 100] [ag; 100] [cd; 100] [ca; 100] [dg; 100] [da; 100] [bd; 1 00] [bf;86] [be;86] [ce;86] [cf;86] [df;86] [de;86] [af;86] [ae;86] [gf;86] [ge;86] [fe;71].
3 phage combinations were analyzed in silico for their ability to lyse the 118 different strains of Staphylococcus aureus bacteria as profiled by their clonal complex, based on the ability of the single phage to lyse a bacteria of a particular clonal complex as assessed by a solid (EOP) assay.
All the combinations below were found to cover 100% of the clonal complexes associated with the 119 bacterial strains. This trait is referred to as “at least 1 phage % coverage.” The number following each combination refers to the Percent trait performance—in this case the percent of bacteria strains as profiled by their clonal complex that are targeted by the phage combination.
[bcd; 100] [bag; 100] [bcg; 100] [bcf; 100] [bce; 100] [bda; 100] [bdg; 100] [bdf; 100] [cdg; 100][bca; 100] [baf; 100] [bae; 100] [bgf; 100] [bge; 100] [bfe; 100] [cda; 100] [bde; 100] [cdf; 100] [daf; 100] [dac; 100] [caf; 100] [cae; 100] [cgf; 100] [cge; 100] [cfe; 100] [dag; 100] [cde; 100] [cag; 100][dgf;100] [dge; 100] [dfe; 100] [agf; 100] [age; 100] [afe; 100] [gfe; 100].
The percent of host bacterial strains (as profiled by their clonal complex) that are infected by two phages of a phage combination are provided below. This trait is referred to as “at least 2 phage % coverage.” All the combinations below were found to have “at least 2 phage % coverage” that equals 100%.
[bcd; 100] [bag; 100] [bcg; 100] [bcf; 100] [bcc; 100] [bda; 100] [bdg; 100] [bdf; 100] [cdg; 100][bca; 100] [baf; 100] [bac; 100] [bgf; 100] [bge; 100] [bfc; 100] [cda; 100] [bde; 100] [cdf; 100] [daf; 100] [dac; 100] [caf; 100] [cac; 100] [cgf; 100] [cge; 100] [cfe; 100] [dag; 100] [cde; 100] [cag; 100][dgf;100] [dge; 100] [dfc; 100] [agf; 100] [age; 100] [afc; 100] [gfc; 100].
The percent of host bacterial strains (as profiled by their clonal complex) that are infected by three phages of a phage combination are provided below. This trait is referred to as “at least 3 phage % coverage.” The phage combinations are ordered in descending performance grade.
[bcd; 100] [cdg; 100] [cag; 100] [bcg; 100] [bda; 100] [bdg; 100] [bca; 100] [bag; 100] [dag; 100] [cda; 100] [baf;86] [bdf;86] [bac;86] [bgf;86] [bcc;86] [bcf;86] [bgc;86] [bde;86] [cdf;86] [daf;86] [agc;86] [agf;86] [dgc;86] [dgf;86] [cde;86] [dac;86] [cgc;86] [cgf;86] [cac;86] [caf;86] [afc;71] [dfe;71] [cfe;71] [bfc;71] [gfc;71].
4 phage combinations were analyzed in silico for their ability to lyse the 118 different strains of Staphylococcus aureus bacteria as profiled by their clonal complex, based on the ability of the single phage to lyse a bacteria of a particular clonal complex as assessed by a solid (EOP) assay.
All combinations that are provided herein below yield 100% coverage by at least one phage of the combination (as profiled by their clonal complex). This trait is referred to as “at least 1 phage % coverage.” The number following each combination refers to the Percent trait performance—in this case the percent of bacteria strains as profiled by their clonal complex that are targeted by the phage combination.
[bcda; 100] [bcfc; 100] [bcdf; 100] [bcde; 100] [bcag; 100] [bcaf; 100] [bcac; 100] [bcgf; 1 00] [bagf; 100] [bcdg; 100] [bdag; 100] [bdaf; 100] [bdac; 100] [bdgf; 100] [bdge; 100] [bdfe; 100] [bcge; 100] [bage; 100] [cagf; 100] [cage; 100] [cdag; 100] [cdaf; 100] [cdac; 100] [cdgf; 100] [cdg c; 100] [cdfe; 100] [bafc; 100] [bgfc; 100] [cafe; 100] [cgfe; 100] [dagf; 100] [dage; 100] [dafe; 100 ][dgfc; 100] [agfc; 100].
The percent of host bacterial strains (as profiled by their clonal complex) that are infected by two phages of a phage combination are provided below. This trait is referred to as “at least 2 phage % coverage.” The phage combinations below all yield 100% coverage.
[bcda; 100] [bcfc; 100] [bcdf; 100] [bcde; 100] [bcag; 100] [bcaf; 100] [bcae; 100] [bcgf; 1 00] [bagf; 100] [bcdg; 100] [bdag; 100] [bdaf; 100] [bdac; 100] [bdgf; 100] [bdge; 100] [bdfe; 100] [bcgc; 100] [bage; 100] [cagf; 100] [cage; 100] [cdag; 100] [cdaf; 100] [cdae; 100] [cdgf; 100] [cdg c; 100] [cdfc; 100] [bafe; 100] [bgfe; 100] [cafe; 100] [cgfc; 100] [dagf; 100] [dage; 100] [dafe; 100][dgfc; 100] [agfe; 100].
The percent of host bacterial strains (as profiled by their clonal complex) that are infected by three phages of a phage combination are provided below. This trait is referred to as “at least 3 phage % coverage.” The phage combinations below all yield 100% coverage.
[bcda; 100] [bcfc; 100] [bcdf; 100] [bcde; 100] [bcag; 100] [bcaf; 100] [bcae; 100] [bcgf; 1 00] [bagf; 100] [bcdg; 100] [bdag; 100] [bdaf; 100] [bdac; 100] [bdgf; 100] [bdge; 100] [bdfe; 100] [bcge; 100] [bage; 100] [cagf; 100] [cage; 100] [cdag; 100] [cdaf; 100] [cdac; 100] [cdgf; 100] [cdg c; 100] [cdfe; 100] [bafe; 100] [bgfe; 100] [cafe; 100] [cgfe; 100] [dagf; 100] [dage; 100] [dafe; 100] [dgfc; 100] [agfe; 100].
The percent of host bacterial strains (as profiled by their clonal complex) that are infected by four phages of a phage combination are provided below. This trait is referred to as “at least 4 phage % coverage.” The phage combinations are ordered in descending performance grade.
[bcda; 100] [bdag; 100] [bcag; 100] [bcdg; 100] [cdag; 100] [bdgf; 86] [bdac;86] [bdaf;86][bdgc;86] [cagf;86] [bcgf;86] [bcac;86] [bcaf;86] [bcde;86] [bcdf;86] [bcge;86] [bagf;86] [bag c;86] [dage;86] [dagf;86] [cdaf;86] [cdac;86] [cdgf;86] [cdge;86] [cage;86] [bgfe;71] [cdfc;71] [bdfe;71] [bcfc;71] [dgfe;71] [bafe;71] [cafe;71] [cgfe;71] [dafe;71 | agfe;71].
5 phage combinations were analyzed in silico for their ability to lyse the 118 different strains of Staphylococcus aureus bacteria as profiled by their clonal complex, based on the ability of the single phage to lyse a bacteria of a particular clonal complex as assessed by a solid (EOP) assay.
The combinations that lyse the highest number of bacterial strains (as profiled by their clonal complex) are provided herein below. This trait is referred to as “at least 1 phage % coverage.” The number following each combination refers to the Percent trait performance—in this case the percent of bacteria strains as profiled by their clonal complex that are targeted by the phage combination. The phage combinations below all yield 100% coverage.
[bcdag; 100] [bcdaf; 100] [bcdae; 100] [bcdgf; 100] [bcdge; 100] [bcdfe; 100] [bcagf; 100] [bcage; 100] [bcafe; 100] [bcgfe; 100] [bdagf; 100] [bdage; 100] [bdafe; 100] [bdgfe; 100] [bagfe; 100] [cdagf; 100] [cdage; 100] [cdafe; 100] [cdgfe; 100] [cagfe; 100] [dagfe; 100].
The percent of host bacterial strains (as profiled by their clonal complex) that are infected by two phages of a phage combination are provided below. This trait is referred to as “at least 2 phage % coverage.” The phage combinations below all yield 100% coverage.
[bcdag; 100] [bcdaf; 100] [bcdae; 100] [bcdgf; 100] [bcdge; 100] [bcdfe; 100] [bcagf; 100] [bcage; 100] [bcafe; 100] [bcgfe; 100] [bdagf; 100] [bdage; 100] [bdafe; 100] [bdgfe; 100] [bagfe; 100] [cdagf; 100] [cdage; 100] [cdafe; 100] [cdgfe; 100] [cagfe; 100] [dagfe; 100].
The percent of host bacterial strains (as profiled by their clonal complex) that are infected by three phages of a phage combination are provided below. This trait is referred to as “at least 3 phage % coverage.” The phage combinations below all yield 100% coverage.
[bcdag; 100] [bcdaf; 100] [bcdae; 100] [bcdgf; 100] [bcdge; 100] [bcdfe; 100] [bcagf; 100] [bcage; 100] [bcafe; 100] [bcgfe; 100] [bdagf; 100] [bdage; 100] [bdafe; 100] [bdgfe; 100] [bagfe; 100] [cdagf; 100] [cdage; 100] [cdafe; 100] [cdgfe; 100] [cagfe; 100] [dagfe; 100].
The percent of host bacterial strains (as profiled by their clonal complex) that are infected by four phages of a phage combination are provided below. This trait is referred to as “at least 4 phage % coverage.” The phage combinations below all yield 100% coverage.
[bcdag; 100] [bcdaf; 100] [bcdae; 100] [bcdgf; 100] [bcdge; 100] [bcdfe; 100] [bcagf; 100] [bcage; 100] [bcafe; 100] [bcgfe; 100] [bdagf; 100] [bdage; 100] [bdafe; 100] [bdgfe; 100] [bagfe; 100] [cdagf; 100] [cdage; 100] [cdafe; 100] [cdgfe; 100] [cagfe; 100] [dagfe; 100].
For this example, the particular phages are referred to by the single letter designation in Table 2, herein above.
2 phage combinations were analyzed in silico for their ability to lyse the 118 different strains of Staphylococcus aureus bacteria as classified by MLST, based on the ability of the single phage to lyse a bacteria of a particular MLST as assessed by a solid (EOP) assay.
The combinations that lyse the highest number of bacterial strains (as classified by MLST) are provided herein below. This trait is referred to as “at least 1 phage % coverage.” The number following each combination refers to the Percent trait performance—in this case the percent of bacteria strains as profiled by their MLSTs that are targeted by the phage combination. The combinations are listed in descending performance grade.
[bd;96] [ae;96] [de;96] [da;96] [ba;96] [bc;93] [af;93] [df;93] [ce;93] [cd;89] [ag;89] [ca; 89] [dg;89] [cf;89] [bg;85] [ge;85] [cg;81] [gf;81] [bf;67] [fe;67] [be;59].
The percent of host bacterial strains (as classified by MLST) that are infected by at least two phages of a phage combination are provided. This trait is referred to as “at least 2 phage % coverage.” The phage combinations are ordered in descending performance grade.
[ca;81] [da;81] [cd;81] [cg;74] [ag;74] [dg;74] [ba;48] [bd;48] [be;48] [bc;44] [de;44] [b g;44] [ae;44] [ce;41] [df;41] [af;41] [ge;41] [cf;37] [gf;37] [bf;33] [fe;30].
3 phage combinations were analyzed in silico for their ability to lyse the 118 different strains of Staphylococcus aureus bacteria as classified by MLST, based on the ability of the single phage to lyse a bacteria of a particular clonal complex as assessed by a solid (EOP) assay.
The combinations that lyse the highest number of bacterial strains (as classified by MLST) are provided herein below. This trait is referred to as “at least 1 phage % coverage.” The number following each combination refers to the Percent trait performance—in this case the percent of bacteria strains as profiled by their MLSTs that are targeted by the phage combination. The combinations are listed in descending performance grade.
[bda; 100] [dae; 100] [dge;96] [afe;96] [bdg;96] [bdf;96] [bde;96] [bag;96] [baf;96] [bae; 96] [age;96] [cda;96] [bca;96] [cde;96] [daf;96] [dag;96] [cae;96] [dfe;96] [bcd;96] [bcg;93] [bc f;93] [bce;93] [caf;93] [cdf;93] [cfe;93] [agf;93] [dgf;93] [cge;93] [cgf;89] [cag;89] [cdg;89] [bg e;85] [bgf;85] [gfe;85] [bfe;67].
The percent of host bacterial strains (as classified by MLST) that are infected by at least two phages of a phage combination are provided below. This trait is referred to as “at least 2 phage % coverage.” The phage combinations are ordered in descending performance grade.
[bda;89] [daf; 89] [dac;89] [bcd;85] [cac;85] [cde;85] [bca;85] [caf;85] [cdf;85] [cdg;81] [dag;81] [cda;81] [cag;81] [bdg;78] [agf;78] [dgf;78] [age;78] [bag;78] [dge;78] [bcg;74] [cge;7 4] [cgf;74] [bdf;63] [gfc;63] [bgf;63] [dfe;63] [bcf;63] [afc;63] [baf;63] [cfe;63] [bce;59] [bae;5 9] [bge;59] [bde;59] [bfc;59].
The percent of host bacterial strains (as classified by MLST) that are infected by three phages of a phage combination are provided below. This trait is referred to as “at least 3 phage % coverage.” The phage combinations are ordered in descending performance grade.
[cda;81] [cdg;74] [cag;74] [dag;74] [bda;44] [bag;44] [bcd;44] [bcg;44] [bca;44] [bdg;4 4] [cgc;41] [dac;41] [bde;41] [age;41] [bac;41] [dge;41] [cde;41] [cac;41] [caf;37] [daf;37] [bge; 37] [dgf;37] [agf;37] [cdf;37] [cgf;37] [bce;37] [baf;30] [bdf;30] [bcf;26] [dfc;26] [afe;26] [bgf; 26] [bfc;26] [cfe;22] [gfc;22].
4 phage combinations were analyzed in silico for their ability to lyse the 118 different strains of Staphylococcus aureus bacteria as classified by MLST, based on the ability of the single phage to lyse a bacteria of a particular MLST as assessed by a solid (EOP) assay.
The combinations that lyse the highest number of bacterial strains (as classified by MLST) are provided herein below. This trait is referred to as “at least 1 phage % coverage.” The number following each combination refers to the Percent trait performance—in this case the percent of bacteria strains as profiled by their MLSTs that are targeted by the phage combination. The combinations are listed in descending performance grade.
[bcda; 100] [dafc; 100] [dage; 100] [cdac; 100] [bdac; 100] [bdaf; 100] [bdag; 100] [bcag;9 6] [bcac;96] [bcdf;96] [bcde;96] [bdge;96] [bcaf;96] [agfc;96] [bdgf;96] [bdfc;96] [bagf;96] [ba ge;96] [bafc;96] [cdge;96] [cdag;96] [dgfe;96] [cdfc;96] [cdaf;96] [bcdg;96] [cage;96] [cafe;96] [dagf;96] [bcge;93] [bcgf;93] [bcfc;93] [cgfc;93] [cdgf;93] [cagf;93] [bgfc;85].
The percent of host bacterial strains (as classified by MLST) that are infected by two phages of a phage combination are provided below. This trait is referred to as “at least 2 phage % coverage.” The phage combinations are ordered in descending performance grade.
[bcac;93] [bcde;93] [bdac;93] [cdfc;89] [bdag;89] [bcaf;89] [dagf;89] [cafc;89] [bcdf;8 9] [bcda;89] [cdaf;89] [bdaf;89] [cdac;89] [dage;89] [dafc;89] [bcge;85] [bdge;85] [cagf;85] [bc ag;85] [cdgf;85] [bage;85] [cagc;85] [bcdg;85] [cdge;85] [bagf;81] [dgfc;81] [agfe;81] [bdgf;8 1] [bcgf;81] [cgfc;81] [cdag;81] [bafe;67] [bdfe;67] [bcfc;67] [bgfc;67].
The percent of host bacterial strains (as classified by MLST) that are infected by three phages of a phage combination are provided below. This trait is referred to as “at least 3 phage % coverage.” The phage combinations are ordered in descending performance grade.
[bcda;81] [cdac;81] [cdag;81] [cdaf;81] [cdge;74] [bdag;74] [cdgf;74] [dagf;74] [cage; 74] [bcdg;74] [bcag;74] [cagf;74] [dage;74] [bdaf;63] [dafc;63] [bcdf;59] [agfe;59] [bcaf;59] [b dgf;59] [cafe;59] [bagf;59] [dgfe;59] [cdfe;59] [cgfe;56] [bcfc;56] [bdfe;56] [bcgf;56] [bgfe;56] [bafe;56] [bdac;56] [bdge;52] [bcde;52] [bcac;52] [bage;52] [bcge;48].
The percent of host bacterial strains (as profiled by MLST) that are infected by four phages of a phage combination are provided below. This trait is referred to as “at least 4 phage % coverage.” The phage combinations are ordered in descending performance grade.
[cdag;74] [bcda;44] [bdag;44] [bcag;44] [bcdg;44] [dage;41] [cdac;41] [cdge;41] [cage; 41] [cagf;37] [cdgf;37] [bcge;37] [bdge;37] [bcde;37] [bcac;37] [bage;37] [dagf;37] [bdae;37] [cdaf;37] [bdgf;26] [bdaf;26] [bagf;26] [bcdf;26] [bcaf;26] [bcgf;26] [dafe;22] [cgfc;22] [bafe;2 2] [bdfe;22] [dgfc;22] [agfe;22] [cdfe;22] [cafe;22] [bcfc; 19] [bgfc; 19].
5 phage combinations were analyzed in silico for their ability to lyse the 118 different strains of Staphylococcus aureus bacteria as classified by MLST, based on the ability of the single phage to lyse a bacteria of a particular MLST as assessed by a solid (EOP) assay.
The combinations that lyse the highest number of bacterial strains (as classified by MLST) are provided herein below. This trait is referred to as “at least 1 phage % coverage.” The number following each combination refers to the Percent trait performance—in this case the percent of bacteria strains as profiled by their clonal complex that are targeted by the phage combination. The combinations are listed in descending performance grade.
[bcdag; 100] [cdafe; 100] [cdage; 100] [bdafe; 100] [bdage; 100] [bdagf; 100] [bcdac; 100] [dagfc; 100] [bcdaf; 100] [bagfe;96] [cagfc;96] [cdgfe;96] [bcdgf;96] [cdagf;96] [bcafe;96] [bd gfc;96] [bcdge;96] [bcdfe;96] [bcagf;96] [bcage;96] [begfe;93].
The percent of host bacterial strains (as classified by MLST) that are infected by at least two phages of a phage combination are provided below. This trait is referred to as “at least 2 phage % coverage.” The phage combinations are ordered in descending performance grade.
[bcafe;93] [bcdfe;93] [bdafe;93] [bdage;93] [bcdac;93] [bcage;93] [bcdge;93] [cagfe;8 9] [cdgfc;89] [bcdgf;89] [cdagf;89] [bcdag;89] [bcagf;89] [bcdaf;89] [dagfc;89] [bdagf;89] [cd age;89] [cdafc;89] [bdgfe;85] [bagfe;85] [bcgfc;85].
The percent of host bacterial strains (as classified by MLST) that are infected by at least three phages of a phage combination are provided below. This trait is referred to as “at least 3 phage % coverage.” The phage combinations are ordered in descending performance grade.
[cdafc;89] [bcdac;89] [bcdaf;89] [bcdag;81] [cdagf;81] [cdage;81] [bdage;81] [bdagf;8 1] [dagfc;81] [cagfc;78] [bcage;78] [bcagf;78] [cdgfc;78] [bcdge;78] [bcdgf;78] [bcafe;63] [ba gfe;63] [bdgfc;63] [bcdfe;63] [bdafe;63] [bcgfe;63].
The percent of host bacterial strains (as classified by MLST) that are infected by at least four phages of a phage combination are provided below. This trait is referred to as “at least 4 phage % coverage.” The phage combinations are ordered in descending performance grade.
[bcdag;74] [cdage;74] [cdagf;74] [cdafe;56] [bdafe;56] [cagfe;56] [bdagf;56] [cdgfc;5 6] [dagfc;56] [bcdgf;56] [bcdaf;56] [bcagf;56] [bdgfe;52] [bagfc;52] [bcafe;52] [bcdfc;52] [bcd ge;48] [bcage;48] [bcdac;48] [bdage;48] [bcgfc;48].
To test the effect on the time till appearance of resistant mutant bacteria (“time to mutant,” TTM) is detected, cocktail ADX2, as well as the individual member phages of the cocktail were tested against different bacterial strains mixtures (termed multi-culture (MC)). 10 bacterial colonies of each bacterial strain tested were picked (˜full 1 μL loop) and transferred into a culture tube prefilled with 4 mL of liquid BHIS and cultured to OD600≥1.5 by shaking, 180 rpm, at 37° C. for ˜16 h. The bacterial culture was diluted using BHIS supplemented with 1 mM MMC ions to reach a final OD of 0.05 and dispensed into a 96-well plate. Each phage was diluted to a concentration of 10
Table 5 presents, for each graph in
S. aureus Isolation from AD Patients
Patients with atopic dermatitis were recruited from Israel and the USA to participate in a sampling study in which skin samples were collected from lesional skin. Skin samples were collected from 1 to 4 areas of lesional skin and plated on ChromAgar plates for selective growth of Staphylococcus species. S. aureus was distinguished based on the morphology of the colonies and further identified as S. aureus using Maldi-Tof.
2-3 bacterial colonies of each strain to be tested were picked and transferred into the same culture tube prefilled with 4 mL of liquid BHIS and cultured to OD600 ≥1.5 by shaking, 180 rpm, at 37° C. for overnight. One culture tube with 4 mL of BHIS only was used as blank.
380 μl of the bacterial culture was transferred into a tube containing 10-12 mL of top-agar (preheated in a thermo-block at 65° C. for at least 30 min). Then, 1 mM final concentration of MMC ions were added, and the tube was mixed gently. The tube contents were poured onto a 12×12 cm BHIS agar plate at RT. The top-agar was allowed to solidify for 15 min at RT. Phage sample was 10-fold serially diluted by pipetting 20 μL of the highest concentration into 180 μL of BHIS. Using a clip-tip, 5 μL of the phage dilutions 100-10-7 were spotted onto the bacterial lawn (prepared in step 3). After 15 min at RT, the plates were placed at 30° C. until visible plaques appeared (˜18 hours).
Phage titer was calculated as follows: (a) The number of plaques at the appropriate dilution (where single plaques can be counted) was multiplied by 200 (1000/5 μL) and by the dilution factor and presented as PFU/mL. (b) EOP was calculated by dividing the PFU/mL obtained on each tested STA strain to the one obtained on the production host according to the following formula:
Bacterial strains on which the EOP was ≥0.1 for the tested phage were considered sensitive.
Specifically, Strain STA163 was deposited on May 10, 2022, at the Polish Collection of micororganisms PCM), Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Ul. Weigla 12, 53-114 Wroclaw, Poland, with accession number B/00393.
Strain STA174 was deposited on May 10, 2022, at the Polish Collection of micororganisms PCM), Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Ul. Weigla 12, 53-114 Wroclaw, Poland, with accession number B/00394.
Strain STA210 was deposited on May 10, 2022, at the Polish Collection of micororganisms PCM), Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Ul. Weigla 12, 53-114 Wroclaw, Poland, with accession number B/00395.
Strain STA236 was deposited on May 10, 2022, at the Polish Collection of micororganisms PCM), Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Ul. Weigla 12, 53-114 Wroclaw, Poland, with accession number B/00397.
Strain STA238 was deposited on May 10, 2022, at the Polish Collection of micororganisms PCM), Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Ul. Weigla 12, 53-114 Wroclaw, Poland, with accession number B/00398.
In this study, isolates of S. aureus from seven patients with AD were tested against phages STA48-1, STA48-5, and STA48-7 (members of ADX2 cocktail). Patients were found to have a single SA strain, across all their lesions, and typically more than one lesion contained the single S. aureus. Table 6 details each phage's sensitive strains. In four out of the seven tested patients (57%), the SA bacteria were sensitive to each tested phage, individualy. In five out of the seven tested patients (71%), the SA bacteria were sensitive to at least one phage of this ADX2 cocktail.
According to certain embodiments, the phages' genomes are reduced in order to create synthetic phages with smaller genomes without a significant hamper of their essential functionality (e.g., the ability to infect and lyse a host bacteria). According to certain embodiments, such a reduced genome can then more readily accommodate a heterogenous molecule of DNA that otherwise, if added to the original full genomic DNA may be challenging due to the limited DNA encapsulation capacity of a phage (see for example Pires, D. P., Monteiro, R., Mil-Homens, D. et al. Designing P. aeruginosa synthetic phages with reduced genomes. Sci Rep 11, 2164 (2021). doi(dot)org/10.1038/s41598-021-81580-2). Additionally, or alternatively, the genetic sequences of the selected phages can be modified or optimized, e.g., for expression in a suitable producer cell line, provided the essential genes are relatively conserved.
According to certain embodiments, the following exemplary method for finding the likely essential genes was used. A gene X was defined as essential if it was recognized and assigned a function by PATRIC (docs(dot)patricbrc(dot)org/). In addition, if the gene's function was unknown by PATRIC (e.g. “hypothetical protein” or “phage protein”) the following test was performed: given a phage genome, for a gene X, count the number of homologs (global amino acid similarity of 30% or more using blastp) in all publicly available phage genomes infecting the same species (num.homologs (gene X)). Subsequently, the mean and standard deviation of number of homologs for each gene in the genomes that were found to contain gene X were computed, and the z-score for gene X was calculated as follows:
Genes with z-scores over-1 were defined essential. All other genes were defined non-essential.
Below, is a list of essential genes for each phage. Each gene is represented by square brackets, containing the following data fields separated by semi-columns: first, the gene's start coordinate, end coordinate, and strand to relate to with relation to the phage genome sequence as presented in the sequence listing (+ is the strand given in the sequence listing). Second, the gene's function. (“HP” denotes a hypothetical protein and “PP” denotes an unclassified phage protein).
[670:1150:-; HP] [1302:1935:-; HP] [2118:2898:-; HP] [2994:3936:-; HP] [4200:4908:-;HP] [4962:5160;-; HP] [5885:6083:-; HP] [6099:6489:-; HP] [6509:6791:-; HP] [6768:7035:-;HP] [8063:8270:+;HP] [8280:8496:+;HP] [8774:9638:+;HP] [9735:9951:+;HP] [10754:109 43: +;HP] [11023:11524:+;HP] [11523:12441:+;HP] [12466:13213:+;HP] [13314:13536:+; HP] [13549:13765:+;HP] [13757:14396:+;HP] [14409:14598:+;HP] [14590:14863:+;HP] [1 5027:15291:+;HP] [15403:15907:+;HP] [16639:17383:+;HP] [17384:18014:+;HP] [18006:18630: +;HP] [18604:18778:+;HP] [18791:19055:+;HP] [19133:21173:+;HP] [21172:21334: +;HP] [21333:21519:+;HP] [21637:22054:+;HP] [22040:22364:+;HP] [22360:22501:+;HP ] [22569:26376:+;HP] [26394:26757:+;HP] [27143:27929:+;HP] [27921:28146:+;HP] [2823 5:28559:+;HP] [28575:29136:+;HP] [29262:29802:+;HP] [29804:30212:+;HP] [30208:304 03: +;HP] [30402:30789:+;HP] [30785:31139:+;HP] [31135:31375:+;HP] [31388:31955:+; HP] [32593:32938:-; HP] [33042:33267:-; HP] [33280:33622:-; HP] [33868:34015:-;HP] [34865:35180:-; HP] [35749:36157:-; HP] [36966:37248:-; HP] [39343:39745:-;HP] [41421:41661:-; HP] [41726:41912:-; HP] [42144:42354:-; HP] [42479:42881:-;HP] [45155:45329:-; HP] [45802:46489:-; HP] [46880:47078:-; HP] [48624:48837:-;HP] [48868:49588:-; HP] [49587:49794:-; HP] [49799:50351:-; HP] [50369:51026:-;HP] [51048:51567:-; HP] [51701:51947:-; HP] [51949:52264:-; HP] [52339:52621:-;HP] [52633:52918:-; HP] [52918:53182:-; HP] [53191:53443:-; HP] [53583:53982:-;HP] [54017:54653:-; HP] [54663:55101:-; HP] [55165:55624:-; HP] [55641:56373:-;HP] [56745:57600:-; HP] [57599:58106:-; HP] [58086:58848:-; HP] [58840:59131:-;HP] [59787:61041:-; HP] [61033:61804:-; HP] [61803:62058:-; HP] [62154:62367:-;HP] [62917:63550:-; HP] [63656:64316:-; HP] [64302:64656:-; HP] [64648:65575:-;HP] [65722:66691:-; HP] [67019:67244:-; HP] [67306:68464:-; HP] [68534:69017:-;HP] [69041:69698:-; HP] [70661:73187:-; HP] [73575:74178:-; HP] [74384:74705:-;HP] [74688:75015:-; HP] [75027:75450:-; Ribonucleoside-diphosphate reductase large subunit] [75663:76380:-; HP] [79732:80851:-; HP] [81682:82120:-; HP] [82488:83565:-;HP] [83578:84172:-; HP] [84155:85634:-; HP] [85810:87094:-; HP] [87568:88012:-;HP] [88272:89304:-; HP] [89373:90063:-; HP] [90279:90999:-; HP] [91323:91581:-;HP] [91580:93020:-; HP] [93012:94236:-; HP] [94608:95730:-; HP] [96148:96604:-;HP] [96691:98056:-; HP] [98061:98418:-; HP] [98435:100349:-; HP] [100338:100509:-;HP] [100560:104019:-; HP] [104038:104560;-; Virion protein 3] [104663:107366:-;HP] [107376:108423:-; HP] [108437:109142:-; HP] [109141:109663:-;HP] [109662:110514:-; HP] [110625:113082:-; HP] [113072:113966:-;HP] [113971:116404:-; HP] [116455:117286:-; HP] [117344:118214:-;HP] [118669:121657:-; HP] [121716:122175:-; HP] [122266:122695:-;HP] [122783:123092:-; HP] [123148:123529:-; HP] [125992:126352:-; Virion protein 5] [126414:128175:-; Putative tail sheath protein] [128197:128404:-; HP] [128403:129240:-;HP] [129258:129879:-; HP] [129878:130754:-; HP] [131045:132254:- ;HP] [132695:133445:-; HP] [133791:135183:-; Major capsid protein] [136231:136996:-;HP] [137172:137877:-; HP] [138501:139458:-; HP] [139498:139741:-;HP] [139869:140163:-; HP].
[186:369:+;HP] [361:664:+;HP] [681:918:+;HP] [941:1310:+;HP] [1358:1535:+;HP] [1538:1709: +;HP] [1711:2194:+;HP] [2241:3489:+;HP] [3503:5789:+;HP] [5902:7342:-;HP] [7316:7739:-; HP] [7740:9504:-; HP] [9559:10012:-; HP] [10029:11046:-;HP] [11108:11870:-; HP] [11876:13814:-; HP] [13826:14603:-; HP] [14574:15558:-;HP] [15572:16784:-; Major capsid protein] [16790:16973:-; HP] [16986:17364;-; HP]
[300:396:+;HP] [416:719:+;HP] [736:973:+;HP] [996:1365:+;HP] [1413:1590:+;HP] [1591:1858: +;HP] [2023:2506:+;HP] [2553:3801:+;HP] [3815:6101:+;HP] [6215:7655:-;HP] [7629:8052:-; HP] [8053:9817:-; HP] [9871:9997:-; HP] [10185:11238:-;HP] [11234:11375:-; HP] [11437:12190:-; HP] [12201:14145:-; HP] [14158:14935:-;HP] [14906:15890:-; HP] [15904:17119:-; Major capsid protein] [17125:17308:-;HP] [17321:17741:-; HP]
[313:409:+;HP] [429:732:+;HP] [749:986:+;HP] [1009:1378:+;HP] [1426:1603:+;HP] [1604:1871: +;HP] [2036:2519:+;HP] [2566:3814:+;HP] [3828:6114:+;HP] [6228:7668:-;HP] [7642:8065:-; HP] [8066:9830:-; HP] [9884:10337:-; HP] [10586:11330:-;HP] [11392:12145:-; HP] [12156:14100:-; HP] [14113:14890:-; HP] [14861:15845:-;HP] [15859:17074:-; Major capsid protein] [17080:17263:-; HP] [17276:17696:-; HP]
[11:320:+;HP] [408:837:+;HP] [928:1387:+;HP] [1446:4434:+;HP] [4888:5758:+;HP] [5816:6641: +;HP] [6692:8891:+;HP] [9367:10573:+;HP] [11013:11907:+;HP] [11897:14354:+;H P] [14465:15317:+;HP] [15316:15838:+;HP] [15837:16542:+;HP| 16556:17603:+;HP] [17 613:20316:+;HP] [20419:20941:+; Virion protein 3] [20960:24419:+;HP] [24470:24641:+;HP] [24630:26544:+;HP] [26559:26916:+;HP] [269 21:28286:+;HP] [28371:28827:+;HP] [29245:30367:+;HP] [30739:31963:+;HP] [31955:33 395: +;HP] [33394:33652:+;HP] [33976:34300:+;HP] [34495:34696:+;HP] [34664:34913:+; HP] [34912:35602:+;HP] [35671:36703:+;HP] [36963:38898:+;Exonuclease subunit 2] [38881:39475:+;HP] [39488:40565:+;HP] [40933:41371:+;HP] [42202:43321:+;HP] [433 36:45070:+;HP] [45900:46827:+;HP] [46839:47166:+;HP] [47149:47470:+;HP] [47676:48 279: +;HP] [48883:49159:+;HP] [49381:52594:+;HP] [52618:53101:+;HP] [53171:54347:+; HP] [54409:54634:+; HP] [54962:55931:+; HP] [56078:57005:+;HP] [56997:57351:+;HP] [5 7337:57997:+; HP] [58103:58736:+;HP] [59286:59499:+; HP] [59595:59850:+;HP] [59849:60620: +;HP] [60612:61866:+;HP] [62522:62813:+;HP] [62805:63567:+;HP] [63547:64054: +;HP] [64053:64908:+;HP] [65280:66012:+;HP] [66029:66488:+;HP] [66552:66990:+;HP ] [67000:67636:+;HP] [67671:68070:+;HP] [68210:68462:+;HP] [68471:68735:+;HP] [6873 5:69020:+;HP] [69032:69326:+;HP] [69389:69704:+;HP] [69706:69952:+;HP] [70086:705 90: +;HP] [70618:71275:+;HP] [71293:71845:+;HP] [71850:72057:+;HP] [72056:72776:+; HP] [72807:73020:+;HP] [73013:73910:+;HP] [74015:74213:+;HP] [74212:74605:+;HP] [7 4604:75081:+;HP] [75141:75336:+;HP] [75848:76883:+;HP] [77884:78292:+;HP] [78417:78627: +;HP] [78859:79045:+;HP] [79110:79338:+;HP] [79800:80151:+;HP] [80290:80629: +;HP] [81087:81489:+;HP] [81514:81874:+;HP] [83149:83458:+;HP] [83567:84191:+;HP] [84317:84599:+;HP] [87375:87690:+;HP] [87761:87998:+;HP] [88074:88365:+;HP] [8838 0:88527:+;HP] [88770:89112:+;HP] [89125:89338:+;HP] [89445:89790:+;HP] [90344:909 11:-; HP] [90924:91164:-; HP] [91160:91514:-; HP] [91510:91897:-; HP] [91896:92088:-;HP] [92087:92495:-; HP] [92497:93016:-; HP] [93142:93703:-; HP] [93719:94043:-;HP] [94132:94357:-; HP] [94349:95135:-; HP] [95521:95884:-; HP] [95902:99709:-;HP] [99777:99918:-; HP] [99914:100238:-; HP] [100224:100641:-; HP] [100759:100945:-;HP] [100944:101106:-; HP] [101105:103145:-; HP] [103223:103487:-;HP] [103500:103674:-; HP] [103648:104272:-; HP] [104264:104894:-;HP] [104895:105639:-; HP] [106371:106875:-; HP] [106987:107251:-;HP] [107415:107688:-; HP] [107680:107869:-; HP] [107882:108521:-;HP] [108513: 108729:-; HP] [108742: 108964:-; HP] [109065: 109635:-;HP] [109830:110259:-; HP] [110728:111646:-; HP] [111645:112146:- ;HP] [112226:112415:-; HP] [113218:113434:-; HP] [113531:113765:-;HP] [113769:113994:-; HP] [114272:114488:-; HP] [114498:114705:-;HP] [115733:116000:+;HP] [115977:116259:+;HP] [116279:116669:+;HP] [116685:11688 3: +;HP] [117608:117806:+;HP] [117860:118568:+;HP] [118832:119774:+;HP] [119870:12 0650: +;HP] [120833:121466:+;HP] [121618:122098:+;HP] [123154:123448:+; HP] [12357 6:123819:+;HP] [123859:124816:+;HP] [125349:126054:+;HP] [126230:126995:+;HP] [12 8043:129435:+; Major capsid protein] [129781:130531:+;HP] [130715:130835:+;HP]: 132027:+;HP] [132026:132647:+;HP] [132665:133502:+;HP] [133501:133708:+; HP] [133730:135491:+;Putative tail sheath protein] [135553:135892:+; Virion protein 5] [137040:137178:+; HP] [137283:137664:+;HP]
[842:1250:+;HP] [1375:1585:+;HP] [1817:2003:+;HP] [2068:2296:+;HP] [2758:3109:+;HP] [4649:4859:+;HP] [4861:5170:+;HP] [5279:5903:+; HP] [6029:6311:+;HP] [9087:9402:+; HP] [9473:9710:+;HP] [9786:10077:+;HP] [10092:10239:+; HP] [10482:10824:+;HP] [1083 7:11050:+;HP] [11157:11502:+;HP] [11791:12166:-; HP] [12454:13015:-;HP][13031:13355:-; HP] [13444:13669:-; HP] [13661:14447:-; HP] [14836:15199:-;HP] [15217:19024:-; HP] [19091:19232:-; HP] [19228:19552:-; HP] [19538:19955:-;HP] [20073:20259:-; HP] [20258:20420:-; HP] [20419:22459:-; HP] [22537:22801:-;HP] [22814:22988:-; HP] [22962:23586:-; HP] [23578:24208:-; HP] [24209:26009:-;HP] [27704:27968:-; HP] [28407:28596:-; HP] [28609:29248:-; HP] [29240:29456:-;HP] [29469:29691:-; HP] [29792:30362:-; HP] [30557:30986:-; HP] [31455:32373:-;HP] [32372:32873:-; HP] [32952:33141:-; HP] [33943:34159:-; HP] [34256:34490:-;HP] [34494:34719:-; HP] [34999:35215:-; HP] [35225:35432:-;HP] [36460:36727:+;HP] [36704:36986:+;HP] [37006:37396:+;HP] [37412:37610:+;HP] [38335:38533:+; HP] [38587:39295:+;HP] [39560:40499:+;HP] [40595:41375:+;HP] [41558:42191: +;HP] [42343:42823:+;HP] [43825:44119:+;HP] [44247:44490:+;HP] [44530:4548 7: +;HP] [46020:46725:+;HP] [46901:47666:+; HP] [48674:50066:+; Major capsid protein] [50412:51162:+;HP] [51346:51466:+;HP] [51782:52658:+;HP] [52657:53278:+;H P] [53296:54133:+;HP] [54132:54339:+;HP] [54361:56122:+;Putative tail sheath protein] [56184:56523:+; Virion protein 5] [57671:57809:+; HP] [57914:58295:+;HP]: 58660:+;HP] [58748:59177:+;HP] [59268:59727:+;HP] [59786:62774:+;HP] [6322 8:64098:+;HP] [64156:64981:+;HP] [65032:67465:+;HP] [67470:68364:+;HP] [68354:708 11: +;HP] [70922:71774:+;HP] [71773:72295:+;HP] [72294:72999:+;HP] [73013:74060:+; HP] [74070:76773:+;HP] [76876:77398:+; Virion protein 3] [77417:80876:+;HP] [80927:81098:+; HP] [81087:83001:+;HP] [83016:83373:+;HP] [83378:84743:+;HP] [8482 8:85284:+;HP] [85702:86824:+;HP] [87196:88420:+;HP] [88412:89852:+;HP] [89851:901 09: +;HP] [90433:90757:+;HP] [90952:91153:+;HP] [91121:91370:+;HP] [91369:92059:+; HP] [92128:93160:+;HP] [93420:95355:+; Exonuclease subunit 2] [95338:95932:+;HP] [95945:97022:+; HP] [97390:97828:+;HP] [98659:99778:+;HP] [99793:101527:+;HP] [102 357:103284:+;HP] [103296:103623:+;HP] [103606:103927:+;HP] [104133:104736:+;HP] [105340:105616:+; HP] [105838:109051:+;HP] [109075:109558:+;HP] [109628:110804:+; HP] [110866:112102:+;HP] [112094:112448:+;HP] [112434:113094:+;HP] [113200:11383 3: +;HP] [114383:114596:+;HP] [114692:114947:+;HP] [114946:115717:+;HP] [115709:11 6963: +;HP] [117619:117910:+;HP] [117902:118664:+;HP] [118644:119151:+;HP] [11915 0:120005:+;HP] [120377:121109:+;HP] [121126:121585:+;HP] [121649:122087:+;HP] [12 2097:122733:+;HP] [122768:123167:+;HP] [123307:123559:+;HP] [123568:123832:+;HP] [123832:124117: +;HP] [124129:124423:+;HP] [124486:124801:+;HP] [124803:125049:+; HP] [125183:125687:+;HP] [125715:126372:+;HP] [126390:126942:+;HP] [126947:12715 4: +;HP] [127153:127873:+;HP] [127904:128117:+;HP] [128110:129007:+;HP] [129112:12 9310: +;HP] [129309:129702:+;HP] [129701:130433:+;HP] [130906:131941:+;HP]
[125:344:+;HP] [1889:2075:+;HP] [2159:2663:+;HP] [2662:4150:+;HP] [4263:4572:+;HP] [4571:5366:+; HP] [5562:6255:+;HP] [6363:6591:+;HP] [6593:6824:+;HP] [6813:7455:+;HP] [7477:7669:+;HP] [7658:7823:+;HP] [8099:8714:+;HP] [8765:9506:+;HP] [9574:9799:+; HP] [9798:10695:+;HP] [10687:11314:+;HP] [11306:11885:+;HP] [12081:12345:+;HP] [12 422:14471:+;HP] [14470:14632:+;HP] [14675:14864:+; HP] [14863:15178:+;HP] [15158:1 5779: +;HP] [15910:16327:+;HP] [16430:16646:+;HP] [16797:17916:+;HP] [17927:18773: +;HP] [19053:19218:+;HP] [19220:19754:+; HP] [19753:20296:+; HP] [20345:20828:+;HP] [20868:21042:+; HP] [21140:21530:+;HP] [21531:21771:+;HP] [21782:21887:+;HP] [2194 9:22687:+;HP] [22676:22871:+;HP] [22871:23090:+;HP] [24541:26392:+;HP] [26484:271 92: +;HP] [27188:27587:+;HP] [27900:28389:+;HP] [28400:28943:+;HP] [28956:29388:+; HP] [29380:29866:+;HP] [29862:30054:+;HP] [30056:30491:+;HP] [30490:30727:+;HP] [3 1059:31239:-; HP] [31323:31593:-; HP] [31592:31766:-; HP] [32474:32711:-;HP] [34120:34501:-; HP] [34600:34924:-; HP] [35091:35250:-;HP] [35850:36339:+;HP] [37162:37450:-; HP] [37655:37964:-;HP] [38273:38612:+;HP] [38816:39164:-; HP] [39174:39414:-; HP] [39509:39767:-;HP] [39770:40064:-; HP] [40171:40357:-; HP] [40372:40672:-; HP] [42707:42902:-;HP] [43909:44206:-; HP] [44270:44468:-; HP] [44469:44862:-; HP] [44878:45124:-;HP] [45202:46672:-; HP] [46689:47598:-; HP] [47594:47903:-; HP] [47996:48260:-;HP] [48287:48488:-; HP] [48500:48725:-; HP] [49195:49510:-; HP] [49876:50194:-;HP] [50196:50460:-; HP] [50474:50654:-; HP] [51237:51765:-; HP] [52406:52712:-;HP] [52788:53052:-; HP] [53168:53456:-; HP] [53472:53766:-; HP] [53767:54169:-;HP] [54395:54575:-; HP] [55682:56033:-; HP] [56047:56353:-; HP] [56422:56701:-;HP] [56700:57048:-; HP] [57060:57429:-; HP] [57441:57624:-; HP] [57671:57968:-;HP] [57960:58137:-; HP] [58148:58397:-; HP] [58411:59056:-; HP] [59136:59370:-;HP] [59362:59614:-; HP] [59603:59780:-; HP] [59815:60373:-; HP] [60377:60620:-;HP] [60766:61165:-; HP] [61226:61931:-; HP] [61947:62391:-; HP] [62455:62914:-;HP] [62931:63663:-; HP] [64034:64898:-; HP] [64897:65344:-; HP] [65321:66089:-;HP] [66081:66618:-; HP] [66681:66993:-; HP] [66979:67348:-; HP] [67361:68612:-;HP] [68604:69360:-; HP] [69363:69624:-; HP] [69718:69946:-; HP] [69960:70482:-;HP] [70495:71128:-; HP] [71254:71917:-; HP] [71903:72257:-; HP] [72260:73529:-;HP] [74946:75429:-; HP] [75757:78976:-; HP] [79052:79358:-; HP] [79367:79964:-;HP] [80170:80491:-; HP] [80474:80804:-; HP] [80821:81871:-; Ribonucleoside-diphosphate reductase subunit beta] [81884:83999:-; Ribonucleoside-diphosphate reductase large subunit] [84013:84406:-; HP] [84422:85031:-; HP] [85017:85470:-; HP] [85872:86940:-;HP] [86954:87551:-; HP] [87550:89470:-; Exonuclease subunit 2] [89469:89847:-;HP] [89846:90872:-; HP] [90950:92393:-; HP] [92385:93999:-; HP] [94010:95759:-;HP] [95849:97226:-; HP] [97232:97604:-; HP] [97625:99548:-; HP] [99548:99707:-;HP] [99755:103214:-; HP] [103234:103756:-; Virion protein 3] [103866:106821:-;HP] [106946:107993:-; HP] [108007:108712:- ; HP] [108711:109236:-;HP] [109235:110027:-; HP] [110133:112680:-; HP] [112679:113567:-;HP] [113580:116007:-; HP] [116085:120141:-; HP] [120196:120733:-;HP] [120776:121235:-; HP] [121367:121679:-; HP| 122121:122580:-;HP] [123281:124217:-; HP] [124887:125268:-; Virion protein 5] [125340:127104:-; Putative tail sheath protein] [127130:127346:-; HP] [127347:128184:-; HP] [128202:128823:-;HP] [128822:129701:-; HP] [129714:130623:-; HP] [131044:132436:-; Major capsid protein] [132551:133508:-; HP] [133526:134267:-; HP] [134494:135997:-;HP] [136189:136501:-; HP] [137004:138156:-; HP] [138249:138729:-;HP] [138885:139707:-; HP] [139699:141517:-; HP] [141531:141858:-;HP] [141938:142217:-; HP] [142194:142461:-; HP] [143485:143692:+;HP] [143704:143914: +;HP]
In this study a liquid assay was used to assess phage infection of bacteria in different growth phases, focusing on stationery state bacteria, which can serve as a proxy for inactive metabolic bacteria (Conlon et al., 2016; Lewis, 2007). Different growth phases represent diverse metabolic states of the bacteria and can thus be used to assess phage infectivity under different metabolic conditions.
A liquid infection assay was conducted on representatives S. aureus strains, to evaluate the activity of ADX2 (phages STA48-1, STA48-5, STA48-7) on early-log, mid-log, and stationary state bacteria.
Methods—Liquid infection and OD readings
10 bacterial colonies of each tested strain were picked (˜full 1 μL loop) and transferred into the same culture tube prefilled with 4 mL of liquid BHIS and cultured to OD600 ≥1.5 by shaking, 180 rpm, at 37° C. for ˜6 h. One culture tube with 4 mL of BHIS only was used as blank. 40 μL of culture was diluted into two culture tubes prefilled with 4 mL of liquid BHIS and incubated by shaking, 180 rpm, at 37° C. until OD600 reached 0.1-0.2 for an early-log phase and 0.6-0.8 for a mid-log phase. The rest of the bacterial culture was incubated by shaking, 180 rpm, at 37° C. for an additional ˜24 h for a stationary growth phase. 96well plates were prepared containing 190 μL of bacterial culture from each bacterial growth phase (early-log, mid-log, and stationery) supplemented with 1 mM (MMC) ions in duplicate of each STA strain. 10 μL the following mixtures was added to the appropriate wells:
The plate also contained duplicate wells of 200 μL BHIS media alone and phage cocktail in BHIS alone to rule out contamination within the media or within the phage cocktail as controls. 50 μL mineral oil was added to each well to prevent evaporation, and the plates were sealed with breathable film. The plates were then placed in a Freedom Evo robotic liquid handler (Tecan) attached to an Infinite M200PRO plate reader (Tecan), heated to 32° C., and gently rotating at 90 rpm. The OD600 of each well was read every ˜20 Min. over 100 hours.
ADX2 phage cocktail is infective in all tested growth states for the strains which were deemed sensitive in a preliminary liquid host range assessment.
A transposable element (TE, transposon, or jumping gene) is a DNA sequence that can change its position within the phage genome, and may be a source of genetic alternations and instability, e.g., by creating or reversing mutations and altering the phage's genetic identity and genome size. Such instability may alter the phage's performance (e.g. with respect to the original host range). Therefore, it is favorable to detect and inactivate TEs.
Using computational methodology, the genomes of the phages of the present invention were screened, and the following transposons were detected:
According to certain embodiments, TEs, such as the ones listed in table 7 are inactivated by complete excision or partial excision of DNA base pairs. For example, the shortest excision of a single base pair may lead to a frame shift in the Transposase enzyme gene (TPase), and/or to impair the function of a structural sequence required for transposon mobility (e.g., insertion and/or excision).
Alternatively, or in addition, the TE may be inactivated by replacement of an original single base pair or more. For example, a change that causes a codon shift, or introduces an early stop codon to the TPase gene, may lead to an inactive version of the translated protein. One of skill in the art can readily envision numerous alternative molecular biology methods known in the art to implement such genetic manipulations, in order to inactivate transposons.
Different models are used to assess phage efficacy in relevant conditions that mimic the human skin. For example, Reconstructed Human Epidermis RHE model may be used for this purpose. It is an in vitro model reconstructed from normal human keratinocytes cultured on an inert polycarbonate filter. This model may be used to test and confirm the phages' efficacy by measuring if the bacterial burden is reduced upon phage treatment. The model may be constructed with different S. aureus strains, allowing one to study the effect of the phages on different phenotypes such as reduction or prevention of biofilm, and efficacy against slow growers. Such studies can be conducted to compare the efficacy of different phages, different formulations, and varying application regimens.
Another model is a mouse model which enables studying phage efficacy in a live organism in the presence of an immune system and potential pathways that may interfere with phage activity. Such a model was used by Nakatsuji et al. (Nature Medicine, 2021) to study reduction of S. aureus on mouse skin that was treated to model atopic dermatitis. Specifically, analysis was conducted on mouse skin after twice-daily topical applications of ShA9 (an antimicrobial agent) or vehicle for 3 days on OVA-sensitized FLGft/ft Balb/c mice that were colonized by S. aureus for 4 days. In this study they monitored live S. aureus recovered from lesional back skin by swab, inflammation, and relative abundance of mRNA of selected cytokines.
Staphylococcus epidermidis (S. epidermidis) is a species of Staphylococcus bacteria that is found in the natural microbiome of human skin. Previous research suggests a potential dual role of S. epidermidis as both non harmful colonizer and pathogen.
To explore the infectivity of phages STA48-1, STA48-5, and STA48-7 (members of ADX2 cocktail) against S. epidermidis, 13 representative strains of S. epidermidis, isolated from human skin, were obtained from IMHA bacterial repository and assessed by EOP analysis. Table 8 below presents a list of the 13 strains of S. epidermidis and the corresponding sensitivity to phage STA48-7 at an EOP of ≥0.1. Two strains of S. epidermidis were found sensitive to STA48-7. All 13 strains of S. epidermidis were found to be resistant to STA48-1 and STA48-5 at that EOP level.
S. epidermidis strain
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications, and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
It is the intent of the applicant(s) that all publications, patents, and patent applications referred to in this specification are to be incorporated in their entirety by reference into the specification, as if each individual publication, patent or patent application was specifically and individually noted when referenced that it is to be incorporated herein by reference. In addition, citation, or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting. In addition, any priority document(s) of this application is/are hereby incorporated herein by reference in its/their entirety.
This application is a U.S. National Stage Application filed under 35 U.S.C. § 371, based on International Patent Application No. PCT/IB2022/054416, filed on May 12, 2022, which claims the benefit of the filing dates of U.S. Provisional Application No. 63/187,484, filed on May 12, 2021, and 63/216,002, filed on Jun. 29, 2021, the entire contents of each of the above-referenced applications, including all drawings and sequence listings, are hereby incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/IB2022/054416 | 5/12/2022 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63216002 | Jun 2021 | US | |
| 63187484 | May 2021 | US |
